Ensheathing Cells and Methylprednisolone	1
Ensheathing Cells	1
Methylprednisolone	23
Axonal Regeneration and Functional Recovery in the Lesioned Adult Rat Spinal Cord Holly H. Nash ,1 Rosemary C. Borke ,1,2 and Juanita J. Anders1 ,2 1Neuroscience Program and 2Department of Anatomy , Physiology , and Genetics , F. Edward He ' bert School of Medicine , Uniformed Services University of the Health Sciences , Bethesda	50
Axonal Regeneration	50
Functional Recovery in the Lesioned Adult Rat Spinal Cord Holly H. Nash ,1 Rosemary C. Borke ,1,2 and Juanita J. Anders1 ,2 1Neuroscience Program and 2Department of Anatomy , Physiology , and Genetics	74
Functional Recovery	74
the Lesioned Adult Rat Spinal Cord Holly H. Nash ,1 Rosemary C. Borke	97
,1,2 and Juanita J. Anders1	166
,1,2	166
Juanita J. Anders1	175
,2 1Neuroscience	193
Program and 2Department of Anatomy , Physiology , and Genetics	210
Program and 2Department	210
Anatomy , Physiology , and Genetics	237
F. Edward He	272
F. Edward	272
He	282
bert School of Medicine , Uniformed Services University of the Health Sciences	286
bert School	286
Medicine , Uniformed Services University of the Health Sciences	301
Medicine , Uniformed Services University	301
the Health Sciences	344
Bethesda	365
Maryland 20814-4799 Axons	375
spinal cord injury -LRB- SCI -RRB- in adult mammals , leading to permanent loss of function	427
spinal cord injury -LRB- SCI -RRB-	427
spinal cord injury	427
SCI	447
adult mammals	455
permanent loss of function	481
permanent loss	481
function	499
SCI	515
ensheathing cells -LRB- ECs -RRB-	520
ensheathing cells	520
ECs	539
recovery in animal models	552
recovery	552
animal models	564
methylprednisolone -LRB- MP -RRB-	587
methylprednisolone	587
MP	607
neurological recovery in humans	620
neurological recovery	620
humans	645
this study	656
the effectiveness of combining ECs and MP after SCI	668
the effectiveness	668
ECs and MP	699
SCI	716
the first time	741
the corticospinal tract	773
adult rats	800
ECs	812
the lesion	839
MP	855
24 hr	879
6 weeks after injury	889
6 weeks	889
injury	903
functional recovery	911
successful performance of directed forepaw reaching -LRB- DFR -RRB- , expressed as percentages	957
successful performance	957
directed forepaw reaching -LRB- DFR -RRB- , expressed as percentages	983
directed forepaw	983
-LRB- DFR -RRB- , expressed as percentages	1009
-LRB- DFR -RRB-	1009
percentages	1029
Axonal regeneration	1042
the number of corticospinal axons	1087
the number	1087
corticospinal axons	1101
biotin dextran tetramethylrhodamine	1149
caudal to the lesion	1186
caudal	1186
the lesion	1196
control rats	1217
either no treatment or vehicle	1241
no treatment	1248
vehicle	1264
abortive axonal regrowth -LRB- 1 mm -RRB- and poor DFR success -LRB- 38 and 42 % , respectively -RRB-	1277
abortive axonal regrowth -LRB- 1 mm -RRB-	1277
abortive axonal regrowth	1277
1 mm	1303
poor DFR success -LRB- 38 and 42 % , respectively -RRB-	1313
poor DFR success	1313
38 and 42 % , respectively	1331
38 and 42 %	1331
38	1331
42 %	1338
controls	1372
MP-treated rats	1382
significantly more axons 7 mm caudal to the lesion	1402
significantly more axons	1402
7 mm caudal to the lesion	1427
7 mm caudal	1427
the lesion	1442
DFR performance	1458
57 %	1502
Rats that received ECs in combination with MP	1508
Rats	1508
ECs	1527
combination	1534
MP	1551
significantly more axons	1558
all other lesioned rats	1588
13 mm	1618
Successful DFR performance	1625
rats with EC transplants , both without -LRB- 72 % -RRB-	1680
rats with EC transplants , both without	1680
rats with EC transplants	1680
rats	1680
EC transplants	1690
72 %	1720
-LRB- 78 % -RRB- MP	1734
78 %	1735
other lesioned rats	1758
These data	1779
previous reports	1798
ECs	1820
axonal regeneration and functional recovery	1832
regeneration	1839
spinal cord lesions	1882
addition	1906
this research	1916
evidence	1939
combination	1967
MP and ECs	1980
axonal regrowth	1999
13 mm caudal	2021
the lesion at 6 weeks after injury	2037
the lesion	2037
6 weeks after injury	2051
6 weeks	2051
injury	2065
Key words	2073
Key	2073
words	2077
animal ; axotomy ; corticospinal tract ; behavioral analysis	2084
animal	2084
axotomy ; corticospinal tract	2092
axotomy	2092
corticospinal tract	2101
behavioral analysis	2122
cells ; fluorescent tracers ; forelimb function ; glia ; neuronal regeneration ; olfactory bulb ; recovery of function ; spinal cord injury ; Sprague Dawley rats Unlike axons	2152
cells	2152
fluorescent tracers	2159
forelimb function	2180
glia	2199
neuronal regeneration	2205
olfactory bulb	2228
recovery of function	2244
recovery	2244
function	2256
spinal cord injury	2266
Sprague Dawley rats Unlike axons	2286
Sprague Dawley rats	2286
axons	2315
the peripheral nervous system -LRB- PNS -RRB- , which have the capacity to regrow -LRB- Fawcett and Keynes , 1990 ; Raivich and Kreutzberg , 1993 -RRB-	2324
the peripheral nervous system -LRB- PNS -RRB-	2324
the peripheral nervous system	2324
PNS	2355
the capacity to regrow -LRB- Fawcett and Keynes , 1990 ; Raivich and Kreutzberg , 1993 -RRB-	2372
Fawcett and Keynes , 1990 ; Raivich and Kreutzberg , 1993	2396
Fawcett and Keynes	2396
1990 ; Raivich and Kreutzberg	2416
1990	2416
Raivich and Kreutzberg	2422
1993	2446
injured CNS axons	2453
Schwab and Bartholdi , 1996 ; Nicholls et al. , 1999	2491
Schwab and Bartholdi	2491
1996 ; Nicholls et al.	2513
1996	2513
Nicholls et al.	2519
Nicholls	2519
et al.	2528
1999	2536
The one exception	2543
the olfactory system	2573
Olfactory neurons	2595
a life span of 4 weeks	2618
a life span	2618
4 weeks	2633
Graziadei and Monti-Graziadei	2642
1978	2673
they	2685
new neurons originating from neuroepithelial precursors located in the olfactory epithelium -LRB- Graziadei and Monti - Graziadei , 1978 -RRB-	2695
new neurons	2695
neuroepithelial precursors located in the olfactory epithelium -LRB- Graziadei and Monti - Graziadei , 1978 -RRB-	2724
neuroepithelial precursors	2724
the olfactory epithelium -LRB- Graziadei and Monti - Graziadei , 1978 -RRB-	2762
the olfactory epithelium	2762
Graziadei and Monti	2788
Graziadei , 1978	2809
Graziadei	2809
1978	2820
the olfactory bulb	2851
functional synapses -LRB- Kosaka et al. , 1998 -RRB-	2879
functional synapses	2879
Kosaka	2900
et al. , 1998	2907
et al.	2907
1998	2915
Fascicles of olfactory axons	2922
Fascicles	2922
olfactory axons	2935
the PNS -LRB- Doucette , 1991 -RRB-	2977
the PNS	2977
Doucette , 1991	2986
Doucette	2986
1991	2996
the CNS -LRB- Doucette , 1993 -RRB-	3011
the CNS	3011
Doucette , 1993	3020
Doucette	3020
1993	3030
a glial cell termed olfactory ensheathing cells -LRB- ECs -RRB- -LRB- Doucette , 1984 -RRB-	3039
a glial cell	3039
olfactory ensheathing cells -LRB- ECs -RRB- -LRB- Doucette , 1984 -RRB-	3059
olfactory ensheathing cells -LRB- ECs -RRB-	3059
olfactory ensheathing cells	3059
ECs	3088
Doucette	3094
1984	3104
their unique ability to promote regeneration in the olfactory system	3120
regeneration	3152
the olfactory system	3168
researchers	3190
transplanted ECs after spinal cord injury -LRB- SCI -RRB- to determine whether ECs retained their ability to promote regeneration	3207
transplanted ECs	3207
spinal cord injury -LRB- SCI -RRB-	3230
spinal cord injury	3230
SCI	3250
ECs	3276
their ability to promote regeneration	3289
regeneration	3314
injection of EC suspensions at the site of a dorsal rhizotomy in rats	3334
injection	3334
EC suspensions at the site of a dorsal rhizotomy in rats	3347
EC suspensions	3347
the site of a dorsal rhizotomy in rats	3365
the site	3365
a dorsal rhizotomy in rats	3377
a dorsal rhizotomy	3377
rats	3399
regenerating axons	3405
the spinal cord gray matter -LRB- Ramon-Cueto and Nieto-Sampedro , 1994 -RRB-	3436
the spinal cord gray matter	3436
Ramon-Cueto and Nieto-Sampedro , 1994	3465
Ramon-Cueto and Nieto-Sampedro	3465
1994	3497
ECs transplanted into spinal cord after electrolytic destruction of the corticospinal tract -LRB- CST -RRB-	3504
ECs	3504
spinal cord	3526
electrolytic destruction of the corticospinal tract	3544
electrolytic destruction	3544
the corticospinal tract	3572
CST	3597
the growth of CST axons	3614
the growth	3614
CST axons	3628
the transplant	3646
the host CST and restoration of directed forepaw reaching -LRB- DFR -RRB- , a measure of function -LRB- Li et al. , 1997 -RRB-	3666
the host CST and restoration	3666
directed forepaw reaching -LRB- DFR -RRB- , a measure of function -LRB- Li et al. , 1997 -RRB-	3698
directed forepaw	3698
-LRB- DFR -RRB- , a measure of function -LRB- Li et al. , 1997 -RRB-	3724
-LRB- DFR -RRB-	3724
a measure of function -LRB- Li et al. , 1997 -RRB-	3731
a measure	3731
function -LRB- Li et al. , 1997 -RRB-	3744
function	3744
Li	3754
et al. , 1997	3757
et al.	3757
1997	3765
a subsequent study using the same experimental model	3775
a subsequent study	3775
the same experimental model	3800
regenerating CST axons	3829
parallel bundles that crossed the lesioned area and reentered the spinal cord after transplantation of ECs into the injury site -LRB- Li et al. , 1998 -RRB-	3866
parallel bundles	3866
the lesioned area	3896
the spinal cord	3928
transplantation of ECs	3950
transplantation	3950
ECs	3969
the injury site	3978
Li	3995
et al. , 1998	3998
et al.	3998
1998	4006
Schwann	4019
cell-filled guidance channels combined with injections of ECs , transected spinal cords	4027
cell-filled guidance channels	4027
injections of ECs	4071
injections	4071
ECs	4085
spinal cords	4101
propriospinal axons that regenerated 2.5 cm -LRB- Ramon - Cueto et al. , 1998 -RRB-	4136
propriospinal axons	4136
2.5 cm -LRB- Ramon - Cueto et al. , 1998 -RRB-	4173
2.5 cm	4173
Ramon	4181
Cueto et al. , 1998	4188
Cueto	4188
et al.	4194
1998	4202
ECs	4219
axonal regeneration	4245
abilities in rats	4286
abilities	4286
rats	4299
complete spinal cord transection -LRB- Ramon-Cueto et al. , 2000 -RRB-	4310
complete spinal cord transection	4310
Ramon-Cueto	4344
et al. , 2000	4356
et al.	4356
2000	4364
ECs	4382
a valuable tool	4404
spinal cord regeneration -LRB- Bartolomei and Greer , 2000 ; Franklin and Barnett , 2000 ; Raisman , 2001 ; Treloar et al. , 2001 -RRB-	4433
spinal cord regeneration	4433
Bartolomei and Greer	4459
Bartolomei	4459
Greer	4474
2000 ; Franklin and Barnett , 2000 ; Raisman , 2001 ; Treloar et al. , 2001	4481
2000	4481
Franklin and Barnett , 2000 ; Raisman , 2001 ; Treloar et al. , 2001	4487
Franklin and Barnett , 2000	4487
Franklin and Barnett	4487
2000	4509
Raisman , 2001	4515
Raisman	4515
2001	4524
Treloar et al. , 2001	4530
Treloar	4530
et al. , 2001	4538
et al.	4538
2001	4546
A common treatment for SCI in human beings	4553
A common treatment	4553
SCI in human beings	4576
SCI	4576
human beings	4583
administration of methylprednisolone -LRB- MP -RRB-	4599
administration	4599
methylprednisolone -LRB- MP -RRB-	4617
methylprednisolone	4617
MP	4637
a synthetic glucocorticoid steroid	4642
its enhanced anti-inflammatory activity	4701
mineralocorticoid activity relative to cortisol , the prototypical glucocorticoid -LRB- Hall , 1992 -RRB-	4754
mineralocorticoid activity	4754
cortisol , the prototypical glucocorticoid	4793
cortisol	4793
the prototypical glucocorticoid	4803
Hall , 1992	4836
Hall	4836
1992	4842
The extreme lipophilicity of MP , a drawback to its intravenous use ,	4849
The extreme lipophilicity of MP	4849
The extreme lipophilicity	4849
MP	4878
a drawback to its intravenous use	4882
a drawback	4882
its intravenous use	4896
the production of an MP-hemisuccinated ester -LRB- Solu-Medrol -RRB-	4938
the production	4938
an MP-hemisuccinated ester -LRB- Solu-Medrol -RRB-	4956
an MP-hemisuccinated ester	4956
Solu-Medrol	4984
Solu-Medrol	5003
the body	5032
the ester	5042
the pro-drug	5070
the free steroid that is believed to cross the blood -- brain barrier -LRB- Hall , 1992 -RRB-	5094
the free steroid	5094
the blood -- brain barrier -LRB- Hall , 1992 -RRB-	5137
the blood	5137
brain barrier -LRB- Hall , 1992 -RRB-	5147
brain barrier	5147
Hall , 1992	5162
Hall	5162
1992	5168
glucocorticoids	5184
clinical treatment of spinal cord trauma	5218
clinical treatment	5218
spinal cord trauma	5240
the 1960s	5265
it	5276
research investigating the neuroprotective pharmacology of MP at various dosing regimens after SCI -LRB- Braughler and Hall , 1982 , 1983 , 1984 ; McGinley et al. , 1982 ; Hall et al. , 1984 ; Braughler et al. , 1987 -RRB- that lead to the first -LRB- Bracken et al. , 1984 -RRB- , second -LRB- Bracken et al. , 1990 -RRB- , and third -LRB- Bracken et al. , 1997 -RRB- National Acute Spinal Cord Injury Study , to optimize parameters for neurological recovery after acute SCI in humans	5290
research	5290
the neuroprotective pharmacology of MP at various dosing regimens	5313
the neuroprotective pharmacology	5313
MP at various dosing regimens	5349
MP	5349
various dosing regimens	5355
SCI -LRB- Braughler and Hall , 1982 , 1983 , 1984 ; McGinley et al. , 1982 ; Hall et al. , 1984 ; Braughler et al. , 1987 -RRB- that lead to the first -LRB- Bracken et al. , 1984 -RRB- , second -LRB- Bracken et al. , 1990 -RRB- , and third -LRB- Bracken et al. , 1997 -RRB- National Acute Spinal Cord Injury Study , to optimize parameters for neurological recovery after acute SCI in humans	5385
SCI	5385
Braughler and Hall , 1982 , 1983 , 1984 ; McGinley et al. , 1982 ; Hall et al. , 1984 ; Braughler et al. , 1987	5390
Braughler and Hall	5390
1982 , 1983 , 1984 ; McGinley et al. , 1982 ; Hall et al. , 1984 ; Braughler et al.	5410
1982 , 1983 , 1984	5410
1982	5410
1983	5416
1984	5422
McGinley et al. , 1982	5428
McGinley	5428
et al. , 1982	5437
et al.	5437
1982	5445
Hall et al. , 1984	5451
Hall	5451
et al. , 1984	5456
et al.	5456
1984	5464
Braughler et al.	5470
Braughler	5470
et al.	5480
1987	5488
the first -LRB- Bracken et al. , 1984 -RRB- , second -LRB- Bracken et al. , 1990 -RRB- , and third -LRB- Bracken et al. , 1997 -RRB-	5507
the first -LRB- Bracken et al. , 1984 -RRB-	5507
the first	5507
Bracken	5518
et al. , 1984	5526
et al.	5526
1984	5534
second -LRB- Bracken et al. , 1990 -RRB-	5541
second	5541
Bracken	5549
et al. , 1990	5557
et al.	5557
1990	5565
third -LRB- Bracken et al. , 1997 -RRB-	5576
third	5576
Bracken	5583
et al. , 1997	5591
et al.	5591
1997	5599
National Acute Spinal Cord Injury Study	5605
National	5605
Acute Spinal Cord Injury Study	5614
parameters for neurological recovery	5658
parameters	5658
neurological recovery	5673
acute SCI	5701
humans	5714
many therapies	5731
regeneration	5757
SCI	5776
it	5816
any single therapy	5840
all of the problems associated with the lack of regeneration after SCI	5870
all	5870
the problems associated with the lack of regeneration after SCI	5877
the problems	5877
the lack of regeneration	5906
the lack	5906
regeneration	5918
SCI	5937
Two therapies shown to promote repair after SCI when used alone	5942
Two therapies	5942
repair	5973
SCI	5986
ECs andMP	6010
we	6032
the effects of combining MP administration with EC transplantation	6044
the effects	6044
MP administration	6069
EC transplantation	6092
regeneration of the CST	6114
regeneration	6114
the CST	6130
injury	6144
we	6157
this combination of treatments	6172
this combination	6172
treatments	6192
longdistance regrowth of CST axons and functional recovery	6212
longdistance regrowth	6212
CST axons and functional recovery	6237
axons	6241
acute cervical SCI in the adult rat	6277
acute cervical SCI	6277
the adult rat	6299
MATERIALS AND METHODS Subjects Eighty-one adult Sprague Dawley rats -LRB- 300 -- 400 gm ; Taconic Farms , Germantown , NY -RRB-	6315
MATERIALS AND METHODS Subjects Eighty-one adult Sprague Dawley rats	6315
MATERIALS	6315
METHODS Subjects Eighty-one adult Sprague Dawley rats	6329
METHODS Subjects	6329
Eighty-one adult Sprague Dawley rats	6346
300	6384
400 gm ; Taconic Farms , Germantown , NY	6388
400 gm	6388
Taconic Farms , Germantown , NY	6396
Taconic Farms	6396
Germantown , NY	6411
this study	6440
Twenty rats	6452
use to harvest ECs for transplants	6469
ECs for transplants	6484
ECs	6484
transplants	6492
61 rats	6509
control and experimental groups	6543
those 61 rats	6579
17	6594
the study	6618
they	6643
14 d	6671
surgery -LRB- n = 15 -RRB-	6682
surgery	6682
n	6691
15	6695
they	6702
response	6726
a food reward	6738
surgery -LRB- n = 2 -RRB-	6759
surgery	6759
n	6768
2	6772
Surgeries Cultures ECs	6776
Surgeries Cultures	6776
ECs	6795
a previously described technique -LRB- Nash et al. , 2001 -RRB-	6837
a previously described technique	6837
Nash	6871
et al. , 2001	6876
et al.	6876
2001	6884
the rats	6900
the nasal and frontal bones	6948
Olfactory nerve rootlets and olfactory bulbs	6990
Olfactory nerve rootlets	6990
olfactory bulbs	7019
The rootlets and outer two layers of the olfactory bulb	7050
The rootlets	7050
outer two layers of the olfactory bulb	7067
outer two layers	7067
the olfactory bulb	7087
the cells	7167
media	7195
a suspension containing 8.5 x 10 5 cells/ml	7220
a suspension	7220
8.5 x 10 5 cells/ml	7244
8.5	7244
10 5 cells/ml	7250
10 5	7250
cells/ml	7255
The cell suspension	7265
an uncoated flask	7301
48 hr , 37 °C and 5 % CO2	7334
48 hr	7334
37 °C	7341
5 % CO2	7350
purification	7362
this 48 hr period	7383
all other cell types in the cell suspension	7402
all other cell types	7402
the cell suspension	7426
the uncoated plastic flask	7458
the ECs	7494
the supernatant	7514
this , our previously described purification process -LRB- Nash et al. , 2001 -RRB-	7537
this , our previously described purification process	7537
this	7537
our previously described purification process	7543
Nash	7590
et al. , 2001	7595
et al.	7595
2001	7603
the ECs	7610
93 %	7640
pure	7644
purification	7662
the ECs	7676
Cell Tracker green -LRB- 50 µM ; Molecular Probes , Eugene , OR -RRB- for immediate transplantation	7718
Cell Tracker green	7718
Cell Tracker	7718
50 µM ; Molecular Probes	7738
50 µM	7738
Molecular Probes	7745
Eugene , OR	7763
Eugene	7763
OR	7771
immediate transplantation	7779
Surgical procedures Rats	7806
control or experimental groups	7857
experimental groups	7868
The three control groups	7889
as follows : sham -LRB- n = 5 -RRB- , lesion -LRB- n = 5 -RRB- , and vehicle -LRB- n = 5 -RRB-	7919
sham -LRB- n = 5 -RRB- , lesion -LRB- n = 5 -RRB- , and vehicle -LRB- n = 5 -RRB-	7931
sham -LRB- n = 5 -RRB-	7931
sham	7931
n	7937
5	7941
lesion -LRB- n = 5 -RRB-	7945
lesion	7945
n	7953
5	7957
vehicle -LRB- n = 5 -RRB-	7965
vehicle	7965
n	7974
5	7978
The three experimental groups	7982
as follows : MP -LRB- n = 10 -RRB- , EC -LRB- n = 9 -RRB- , and MP/EC -LRB- n = 10 -RRB-	8017
MP -LRB- n = 10 -RRB- , EC -LRB- n = 9 -RRB- , and MP/EC -LRB- n = 10 -RRB-	8029
MP -LRB- n = 10 -RRB-	8029
MP	8029
n	8033
10	8037
EC -LRB- n = 9 -RRB-	8042
EC	8042
n	8046
9	8050
MP/EC -LRB- n = 10 -RRB-	8058
MP/EC	8058
n	8065
10	8069
anesthesia with isoflurane -LRB- 5 % ; Abbott Laboratories , North Chicago , IL -RRB- and application of ophthalmic ointment -LRB- E. Fougera & Co. , Melville , NY -RRB-	8080
anesthesia with isoflurane -LRB- 5 % ; Abbott Laboratories , North Chicago , IL -RRB-	8080
anesthesia	8080
isoflurane -LRB- 5 % ; Abbott Laboratories , North Chicago , IL -RRB-	8096
isoflurane	8096
5 % ; Abbott Laboratories	8108
5 %	8108
Abbott Laboratories	8112
North Chicago , IL	8133
North Chicago	8133
IL	8148
application of ophthalmic ointment -LRB- E. Fougera & Co. , Melville , NY -RRB-	8156
application	8156
ophthalmic ointment -LRB- E. Fougera & Co. , Melville , NY -RRB-	8171
ophthalmic ointment	8171
E. Fougera & Co. , Melville , NY	8192
E. Fougera & Co.	8192
Melville , NY	8210
the rats	8225
an operating board in such a way	8249
an operating board	8249
such a way	8271
the cervical spinal cord	8293
maximum exposure	8322
A laminectomy	8340
the dorsum of the spinal cord between C2 and C4	8377
the dorsum	8377
the spinal cord between C2 and C4	8391
the spinal cord	8391
C2 and C4	8415
The dorsal columns	8426
all rats except for those in the sham group	8482
all rats	8482
those in the sham group	8502
those	8502
the sham group	8511
a suture needle	8527
the spinal cord	8562
the dorsal funiculus	8589
The suture thread	8611
a pair of iridectomy scissors	8652
a pair	8652
iridectomy scissors	8662
the dorsal funiculus	8715
the dorsal CST	8757
Visualization of the dorsal horns and the central gray commissure	8773
Visualization	8773
the dorsal horns and the central gray commissure	8790
the dorsal horns	8790
the central gray commissure	8811
accuracy of the lesion borders	8849
accuracy	8849
the lesion borders	8861
ECs	8881
Cell	8901
Tracker green	8906
10 µl Hamilton syringe	8935
10 µl	8935
Hamilton syringe	8941
the cut surfaces of the CST -LRB- two injections in the rostral surface and two in the caudal surface -RRB-	8964
the cut surfaces	8964
the CST -LRB- two injections in the rostral surface and two in the caudal surface -RRB-	8984
the CST	8984
two injections in the rostral surface and two in the caudal surface	8993
two injections in the rostral surface	8993
two injections	8993
the rostral surface	9011
two in the caudal surface	9035
two	9035
the caudal surface	9042
The injections	9063
the cut surface of the spinal cord	9099
the cut surface	9099
the spinal cord	9118
each injection	9139
≈ 500 µm lateral	9158
the posterior median septum and ≈ 500 µm dorsal	9177
the posterior median septum	9177
≈ 500 µm dorsal	9209
the central gray matter	9227
Each injection site	9252
0.5 µl of a suspension containing 50,000 ECs in DMEM -LRB- Biofluids , Rockville , MD -RRB-	9281
0.5 µl	9281
a suspension containing 50,000 ECs in DMEM -LRB- Biofluids , Rockville , MD -RRB-	9291
a suspension	9291
50,000 ECs in DMEM -LRB- Biofluids , Rockville , MD -RRB-	9315
50,000 ECs	9315
DMEM -LRB- Biofluids , Rockville , MD -RRB-	9329
DMEM	9329
Biofluids	9335
Rockville	9346
MD	9357
injections	9366
≈ 2 min	9414
Rats receiving the vehicle for ECs	9422
Rats	9422
the vehicle for ECs	9437
the vehicle	9437
ECs	9453
an equal volume of DMEM	9476
an equal volume	9476
DMEM	9495
the CST	9505
A pledget of biodegradable Gelfoam	9514
A pledget	9514
biodegradable Gelfoam	9527
Fluorogold -LRB- 3 % in 0.9 % saline ; Molecular Probes -RRB-	9559
Fluorogold	9559
3 % in 0.9 % saline ; Molecular Probes	9571
3 %	9571
0.9 % saline ; Molecular Probes	9577
0.9 % saline	9577
Molecular Probes	9590
the lesion site -LRB- see Tracers below -RRB-	9622
the lesion site	9622
Tracers	9643
The overlying muscles and skin	9659
the rats	9708
a heating pad	9732
body temperature	9758
Each rat	9776
a single dose of buprenorphine -LRB- 0.1 mg/kg ; Reckitt & Colman Pharmaceuticals , Richmond , VA -RRB-	9794
a single dose	9794
buprenorphine -LRB- 0.1 mg/kg ; Reckitt & Colman Pharmaceuticals , Richmond , VA -RRB-	9811
buprenorphine	9811
0.1 mg/kg ; Reckitt & Colman Pharmaceuticals	9826
0.1 mg/kg	9826
Reckitt & Colman Pharmaceuticals	9837
Richmond , VA	9871
Richmond	9871
VA	9881
surgery	9903
pain	9924
One hour after the spinal cord	9930
One hour	9930
the spinal cord	9945
a bolus injection of MP sodium succinate -LRB- Solu-Medrol , 30 mg/kg ; Pharmacia Upjohn , Kalamazoo , MI -RRB- in 0.9 % saline	9975
a bolus injection	9975
MP sodium succinate -LRB- Solu-Medrol , 30 mg/kg ; Pharmacia Upjohn , Kalamazoo , MI -RRB- in 0.9 % saline	9996
MP sodium succinate -LRB- Solu-Medrol , 30 mg/kg ; Pharmacia Upjohn , Kalamazoo , MI -RRB-	9996
MP sodium succinate	9996
Solu-Medrol , 30 mg/kg ; Pharmacia Upjohn , Kalamazoo , MI	10017
Solu-Medrol	10017
30 mg/kg ; Pharmacia Upjohn	10030
30 mg/kg	10030
Pharmacia Upjohn	10040
Kalamazoo , MI	10058
0.9 % saline	10076
a tail vein	10109
This injection	10122
four subsequent administrations of MP	10153
four subsequent administrations	10153
MP	10188
a tail vein -LRB- 30 mg/kg -RRB- at 6 hr intervals	10196
a tail vein -LRB- 30 mg/kg -RRB-	10196
a tail vein	10196
30 mg/kg	10209
6 hr intervals	10222
Rats receiving vehicle for MP	10238
Rats	10238
vehicle for MP	10253
vehicle	10253
MP	10265
the same treatment regimen	10278
an equal volume of 0.09 % saline in a tail vein	10328
an equal volume	10328
0.09 % saline in a tail vein	10347
0.09 % saline	10347
a tail vein	10363
all lesioned rats	10380
their bladders	10399
surgery and three times per day	10456
surgery	10456
three times per day	10468
three times	10468
day	10484
spontaneous urination	10494
Tracers During surgery -LRB- see Surgical procedures -RRB- , a fluorescent retrograde tracer , Fluorogold ,	10526
Tracers During surgery -LRB- see Surgical procedures -RRB-	10526
Tracers	10526
surgery	10541
Surgical procedures	10554
a fluorescent retrograde tracer , Fluorogold	10576
a fluorescent retrograde tracer	10576
Fluorogold	10609
the neurons whose axons were transected	10650
the neurons	10650
axons	10668
the lesion	10702
Seven weeks	10714
injury	10732
rats	10740
injection of biotin dextran tetramethylrhodamine -LRB- BDT ; Molecular Probes -RRB-	10763
injection	10763
biotin dextran tetramethylrhodamine -LRB- BDT ; Molecular Probes -RRB-	10776
biotin dextran tetramethylrhodamine	10776
BDT ; Molecular Probes	10813
BDT	10813
Molecular Probes	10818
This fluorescent anterograde tracer , injected into the primary motor cortex ,	10837
This fluorescent anterograde tracer	10837
the primary motor cortex	10888
CST axons	10932
the lesion site in the spinal cord	10952
the lesion site	10952
the spinal cord	10971
anesthesia with isoflurane -LRB- 5 % -RRB-	10994
anesthesia	10994
isoflurane -LRB- 5 % -RRB-	11010
isoflurane	11010
5 %	11022
rats	11027
a stereotaxic instrument	11047
a total of six stereotaxically determined holes -LRB- 0.9 mm diameter -RRB-	11077
a total	11077
six	11088
holes -LRB- 0.9 mm diameter -RRB-	11119
holes	11119
0.9 mm diameter	11126
the skull over the primary motor cortices associated with the forelimbs	11159
the skull	11159
the primary motor cortices associated with the forelimbs	11174
the primary motor cortices	11174
the forelimbs	11217
The anteroposterior -LRB- AP -RRB- and mediolateral -LRB- ML -RRB-	11232
The anteroposterior -LRB- AP -RRB-	11232
The anteroposterior	11232
AP	11253
mediolateral -LRB- ML -RRB-	11261
mediolateral	11261
ML	11275
these injections , from bregma ,	11295
these injections	11295
bregma	11318
+0.5 AP and ± 3.5 ML ; +1.5 A/P and ± 2.5 ML ; and +2.5 AP and ±	11343
+0.5 AP and ± 3.5 ML	11343
+0.5 AP	11343
± 3.5 ML	11355
+1.5 A/P and ± 2.5 ML	11364
+1.5 A/P	11364
± 2.5 ML	11377
+2.5 AP and ±	11390
+2.5 AP	11390
±	11402
1.5 ML	11403
All injections	11411
a depth of 2.5 mm	11444
a depth	11444
2.5 mm	11455
the surface of the skull	11467
the surface	11467
the skull	11482
A 10 µl Hamilton syringe	11493
BDT	11537
layer V of the cortex	11558
layer V	11558
the cortex	11569
Three injections into each cortical hemisphere	11581
Three injections	11581
each cortical hemisphere	11603
a total of 1.2 µl of the anterograde tracer	11652
a total	11652
1.2 µl of the anterograde tracer	11663
1.2 µl	11663
the anterograde tracer	11673
Bone wax -LRB- Ethicon , Somerville , NJ -RRB-	11697
Bone wax	11697
Ethicon	11707
Somerville	11716
NJ	11728
the holes	11749
the skull	11762
the scalp	11773
a single dose of buprenorphine -LRB- 0.1 mg/kg -RRB-	11800
a single dose	11800
buprenorphine -LRB- 0.1 mg/kg -RRB-	11817
buprenorphine	11817
0.1 mg/kg	11832
surgery	11878
pain	11899
Rats	11905
3 d	11922
tracer injections	11932
Functional testing Apparatus A modified version of an apparatus -LRB- Castro , 1972 -RRB- designed to test DFR	11951
Functional testing Apparatus A	11951
version of an apparatus -LRB- Castro , 1972 -RRB- designed to test DFR	11991
version	11991
an apparatus -LRB- Castro , 1972 -RRB- designed to test DFR	12002
an apparatus	12002
Castro	12016
1972	12024
DFR	12047
ability -LRB- Fig. 1A , B -RRB-	12080
ability	12080
Fig. 1A , B	12089
Fig. 1A	12089
B	12097
The apparatus	12101
a box with two compartments separated by a Plexiglas divider	12119
a box	12119
two compartments separated by a Plexiglas divider	12130
two compartments	12130
a Plexiglas divider	12160
The two compartments	12181
a main compartment -LRB- 30.5 x 6.25 x 5 inches -RRB- for the rat and a minor compartment -LRB- 30.5 x 3.5 x 3 inches -RRB-	12212
a main compartment -LRB- 30.5 x 6.25 x 5 inches -RRB-	12212
a main compartment	12212
30.5	12232
x 6.25 x 5 inches	12237
6.25	12239
5 inches	12246
the rat and a minor compartment	12260
the rat	12260
a minor compartment	12272
30.5	12293
x 3.5 x 3 inches	12298
3.5	12300
3 inches	12306
the food reward , which was subdivided into 14 adjacent slots of equal size -LRB- 2 x 1.25 x 3 inches -RRB-	12320
the food reward	12320
14 adjacent slots of equal size -LRB- 2 x 1.25 x 3 inches -RRB-	12363
14 adjacent slots	12363
equal size -LRB- 2 x 1.25 x 3 inches -RRB-	12384
equal size	12384
2	12396
x 1.25 x 3 inches	12398
1.25	12400
3 inches	12407
The floor of the minor compartment	12418
The floor	12418
the minor compartment	12431
a movable shelf	12465
The shelf	12482
a 0.75 inch opening in the floor between the compartments	12527
a 0.75 inch opening	12527
the floor between the compartments	12550
the floor	12550
the compartments	12568
Testing procedures	12613
a continuous floor between the two compartments	12644
a continuous floor	12644
the two compartments	12671
All presurgical and postsurgical testing	12693
the three-quarter inch opening in the floor	12753
the three-quarter inch opening	12753
the floor	12787
The Plexiglas divider -LRB- 30.75 x 0.25 x 5 inches -RRB- separating the rat compartment from the food compartment	12798
The Plexiglas divider -LRB- 30.75 x 0.25 x 5 inches -RRB-	12798
The Plexiglas divider	12798
30.75	12821
x 0.25 x 5 inches	12827
0.25	12829
5 inches	12836
the rat compartment	12857
the food compartment	12882
14 semicircular holes drilled into the bottom , each of which was 0.50 inches in diameter A single 190 mg food pellet -LRB- Bio-Serv , Frenchtown , NJ -RRB- was placed into each of the 14 slots in the minor compartment	12907
14 semicircular holes	12907
the bottom , each of which was 0.50 inches in diameter A single 190 mg food pellet -LRB- Bio-Serv , Frenchtown , NJ -RRB- was placed into each of the 14 slots in the minor compartment	12942
the bottom	12942
each	12954
0.50 inches in diameter A	12972
0.50 inches	12972
diameter A	12987
190 mg food pellet -LRB- Bio-Serv , Frenchtown , NJ -RRB-	13005
190 mg food pellet	13005
Bio-Serv	13025
Frenchtown	13035
NJ	13047
each of the 14 slots	13067
each	13067
the 14 slots	13075
the minor compartment	13091
The rats	13114
a forelimb	13147
the holes in the Plexiglas divider	13166
the holes	13166
the Plexiglas divider	13179
a food pellet	13210
The rats	13225
the food pellet	13272
the holes in the Plexiglas divider	13293
the holes	13293
the Plexiglas divider	13306
one limb at a time	13360
one limb	13360
a time	13372
The opening in the floor	13380
The opening	13380
the floor	13395
the rats	13418
the food	13446
pellet	13455
it	13474
a rat	13481
a pellet	13514
the slot	13530
it	13568
the pellet	13572
the opening in the floor	13616
the opening	13616
the floor	13631
Testing procedures	13642
surger y. Rats	13668
food restricted	13688
3 gm food/100 gm	13716
body weight	13733
day , before	13749
day	13749
training and testing	13776
Weight	13798
rats	13834
no less than 80 % of heir original body weight	13855
no less than 80 %	13855
heir original body weight	13875
any time	13904
All rats	13914
shaping	13934
periods for 2 -- 3 d in the box to allow them to learn the task while they became familiar with the testing situation	13942
periods for 2	13942
periods	13942
2	13954
3 d in the box to allow them to learn the task while they became familiar with the testing situation	13956
3 d	13956
the box to allow them to learn the task while they became familiar with the testing situation	13963
them	13980
the task	13994
they	14009
the testing situation	14035
these shaping periods	14065
the Plexiglas divider	14088
1 inch	14131
the floor	14144
0.25 inches	14171
flush	14204
the floor	14218
all rats	14229
this most stringent level	14265
It	14292
rats	14322
a paw preference that can be disrupted after unilateral lesioning of the neurons or axons corresponding to the preferred limb -LRB- Castro , 1977 ; Kartje-Tillotson and Castro , 1980 -RRB-	14335
a paw preference	14335
unilateral lesioning of the neurons or axons corresponding to the preferred limb -LRB- Castro , 1977 ; Kartje-Tillotson and Castro , 1980 -RRB-	14380
unilateral lesioning	14380
the neurons or axons corresponding to the preferred limb -LRB- Castro , 1977 ; Kartje-Tillotson and Castro , 1980 -RRB-	14404
the neurons or axons	14404
the preferred limb -LRB- Castro , 1977 ; Kartje-Tillotson and Castro , 1980 -RRB-	14442
the preferred limb	14442
Castro , 1977 ; Kartje-Tillotson and Castro , 1980	14462
Castro	14462
1977 ; Kartje-Tillotson and Castro	14470
1977	14470
Kartje-Tillotson and Castro	14476
1980	14505
our study	14515
a bilateral lesion	14535
both paws	14593
data on paw preference	14615
data	14615
paw preference	14623
Animals	14657
day for 5 d	14688
day	14688
5 d	14696
day for 5 d	14726
day	14726
5 d	14734
presurgical DFR data	14743
the testing period	14787
rats	14807
5 min	14823
the task	14841
many attempts	14878
they	14895
this time period	14914
Rats	14932
at least 95 % of their original weight	14964
at least 95 %	14964
their original weight	14980
they	15017
surgery	15053
surger y. Rats	15068
week	15106
weeks	15118
2 -- 5 after surgery	15124
2 -- 5	15124
surgery	15134
Some rats	15143
they	15183
the grasping portion of the DFR task in the early postsurgical period	15209
the grasping portion	15209
the DFR task	15233
the early postsurgical period	15249
the food reward	15328
those rats	15349
the opening in the floor of the apparatus	15361
the opening	15361
the floor of the apparatus	15376
the floor	15376
the apparatus	15389
the food to be raked into the main compartment	15423
the main compartment	15449
the reaching portion of the DFR task	15485
the reaching portion	15485
the DFR task	15509
The severity of the grasping impairment	15542
The severity	15542
the grasping impairment	15558
the postsurgical period	15595
the opening in the floor	15634
the opening	15634
the floor	15649
the end of the postsurgical recovery period	15691
the end	15691
the postsurgical recovery period	15702
all rats	15736
successf ully	15758
the DFR task , to some degree ,	15780
the DFR task	15780
some degree	15797
the 0.75 inch opening	15815
the floor of the apparatus	15840
the floor	15840
the apparatus	15853
the sixth week after surgery	15875
the sixth week	15875
surgery	15896
rats	15905
day for 5 d	15932
day	15932
5 d	15940
postsurgical DFR data	15949
a blinded investigator	15989
the presurgery testing period	16028
the rats	16059
5 min	16081
the task	16099
the postsurgery testing period	16115
many attempts	16174
they	16191
this time period	16210
The data	16228
terms of total number of attempts and percentage of successf ul attempts	16255
terms	16255
total number of attempts and percentage of successf ul attempts	16264
total number	16264
attempts and percentage	16280
successf ul attempts	16307
An attempt	16329
a rat	16361
a slot	16380
the pellet	16401
it	16423
the gap in the floor	16434
the gap	16434
the floor	16445
A successf ul attempt	16456
a rat	16494
a pellet	16508
it	16525
the gap in the floor	16533
the gap	16533
the floor	16544
it	16566
the Plexiglas divider	16577
the pellet	16602
the main portion of the testing apparatus	16620
the main portion	16620
the testing apparatus	16640
This conservative method of counting	16663
This conservative method	16663
counting	16691
arbitrariness	16719
the investigator	16736
interpretation of the data	16775
interpretation	16775
the data	16793
Data	16803
the statistical software program Prism	16828
A one-way ANOVA	16868
an alpha-level of 0.05	16904
an alpha-level	16904
0.05	16922
a Bonferroni 's multiple comparison test	16940
a Bonferroni 's	16940
Data	16981
mean ± SEM percentages	17003
Histology Seven weeks and 3	17027
Histology Seven weeks	17027
3	17053
rats	17074
chloral hydrate -LRB- 10 ml/kg ; Sigma , St. Louis , MO -RRB-	17102
chloral hydrate	17102
10 ml/kg ; Sigma	17119
10 ml/kg	17119
Sigma	17129
St. Louis , MO	17136
St. Louis	17136
MO	17147
300 ml of PBS , pH 7.4 ,	17184
300 ml	17184
PBS , pH 7.4 ,	17194
PBS	17194
pH 7.4	17199
300 ml of 4 % paraformaldehyde in 0.1 M phosphate buffer	17219
300 ml	17219
4 % paraformaldehyde in 0.1 M phosphate buffer	17229
4 % paraformaldehyde	17229
0.1 M phosphate buffer	17252
the animals	17282
all brains and spinal cords	17307
all brains	17307
spinal cords	17322
overnight in 30 % sucrose	17359
overnight	17359
30 % sucrose	17372
a 0.1 M phosphate buffer solution	17387
The brains	17422
the spinal cords	17456
a thickness of 20 µm with a freezing microtome	17498
a thickness	17498
20 µm with a freezing microtome	17513
20 µm	17513
a freezing microtome	17524
ProbeOn -LRB- Fisher Scientific , Pittsburgh , PA -RRB-	17560
ProbeOn	17560
Fisher Scientific	17569
Pittsburgh	17588
PA	17600
coated slides	17604
Brain and spinal cord sections	17619
a Nikon -LRB- Tokyo , Japan -RRB- Labophot fluorescent microscope , and images	17670
a Nikon -LRB- Tokyo , Japan -RRB- Labophot fluorescent microscope	17670
Nikon -LRB- Tokyo , Japan -RRB- Labophot	17672
Tokyo	17679
Japan	17686
images	17730
a Sony -LRB- Tokyo , Japan -RRB-	17757
a Sony	17757
Tokyo	17765
Japan	17772
DKC 5000 Catseye digital still camera	17779
DKC 5000	17779
Catseye digital still camera	17788
Catseye	17788
digital still camera	17796
The forelimb representation of the primary motor cortex	17818
The forelimb representation	17818
the primary motor cortex	17849
the stereotaxic BDT injection sites	17898
Detection of Fluorogold-labeled neurons in layer V of the forelimb representation of the primary motor cortex	17935
Detection	17935
Fluorogold-labeled neurons in layer V of the forelimb representation of the primary motor cortex	17948
Fluorogold-labeled neurons	17948
layer V of the forelimb representation of the primary motor cortex	17978
layer V	17978
the forelimb representation of the primary motor cortex	17989
the forelimb representation	17989
the primary motor cortex	18020
lesioning of the CST	18055
lesioning	18055
the CST	18068
Fluorogold	18085
cut axons but not intact axons	18111
cut axons	18111
intact axons	18129
Axonal counts The spinal cord caudal to the lesion was examined , and the BDT-labeled axons occupying the region of the spinal cord normally occupied by the dorsal CST	18143
Axonal counts	18143
The spinal cord caudal to the lesion	18157
The spinal cord caudal	18157
the lesion	18183
the BDT-labeled axons	18212
the region of the spinal cord normally occupied	18244
the region	18244
the spinal cord normally occupied	18258
the spinal cord	18258
the dorsal CST	18295
a biomedical statistician	18346
it	18373
a 95 % confidence level and an SD of 10 axons	18402
a 95 % confidence level	18402
an SD of 10 axons	18429
an SD	18429
10 axons	18438
a sampling fraction of 1:4 sections	18448
a sampling fraction	18448
1:4 sections	18471
a precision of X ± 5.4 axons	18500
a precision	18500
X ± 5.4 axons	18515
X	18515
± 5.4 axons	18517
A random starting section to begin counts	18530
A random starting section	18530
counts	18565
a number between 1 and 4	18609
a number	18609
1 and 4	18626
each section	18639
the number of BDT-labeled axons	18653
the number	18653
BDT-labeled axons	18667
3 mm intervals caudal to the lesion , beginning 1 mm distal to the injury -LRB- i.e. , 1 mm , 4 mm , 7 mm , etc. -RRB- and ending 19 mm caudal to the lesion site	18700
3 mm intervals	18700
the lesion	18725
1 mm distal to the injury -LRB- i.e. , 1 mm , 4 mm , 7 mm , etc. -RRB-	18747
1 mm	18747
the injury	18762
i.e. , 1 mm , 4 mm , 7 mm , etc.	18774
i.e. , 1 mm	18774
i.e.	18774
1 mm	18780
4 mm	18786
7 mm	18792
19 mm caudal	18815
the lesion site	18831
Innervation of the rat forepaw	18848
Innervation	18848
the rat forepaw	18863
T1 , a distance of 15.1 mm	18890
T1	18890
a distance of 15.1 mm	18894
a distance	18894
15.1 mm	18908
the lesion at C3	18921
the lesion	18921
C3	18935
analysis of the axons	18950
analysis	18950
the axons	18962
19 mm caudal to the lesion	18979
19 mm caudal	18979
the lesion	18995
the entire distance representing the forepaw	19019
the entire distance	19019
the forepaw	19052
each interval	19081
the total number of BDT-labeled axons -LRB- left and right CST combined -RRB- along a 500 µm length -LRB- length of microscope field -RRB-	19096
the total number	19096
BDT-labeled axons -LRB- left and right CST combined -RRB- along a 500 µm length -LRB- length of microscope field -RRB-	19116
BDT-labeled axons -LRB- left and right CST combined -RRB-	19116
BDT-labeled axons	19116
left and right CST combined	19135
left and right CST	19135
a 500 µm length -LRB- length of microscope field -RRB-	19170
a 500 µm length	19170
length of microscope field	19187
length	19187
microscope field	19197
each field counted	19231
each field	19231
the focal plane	19251
a single continuous axon	19307
it	19358
the focal plane	19378
the same field	19424
the data	19446
they	19470
the statistical software program Prism	19495
A one-way ANOVA	19535
an alpha-level of 0.05	19571
an alpha-level	19571
0.05	19589
a Bonferroni 's multiple comparison test for the data from all of the groups at each interval counted	19607
a Bonferroni 's multiple comparison test	19607
a Bonferroni 's	19607
the data from all of the groups at each interval counted	19651
the data	19651
all of the groups at each interval counted	19665
all	19665
the groups at each interval counted	19672
the groups	19672
each interval counted	19686
each interval	19686
Data	19709
mean ± SEM number of axons	19731
mean ± SEM number	19731
axons	19752
RESULTS Figure 1 .	19760
RESULTS	19760
Figure 1	19768
DFR apparatuses and functional performance .	19778
DFR	19778
apparatuses and functional performance	19782
apparatuses	19782
functional performance	19798
A , A schematic of the DFR apparatus , viewed from the front , with the opening in the floor at 0.75 inches .	19822
A , A schematic of the DFR apparatus , viewed from the front , with the opening in the floor at 0.75 inches	19822
A , A schematic of the DFR apparatus ,	19822
A schematic	19825
the DFR apparatus	19840
the front	19871
the opening in the floor at 0.75 inches	19887
the opening	19887
the floor at 0.75 inches	19902
the floor	19902
0.75 inches	19915
The circles	19928
food pellets used as a reward	19950
food pellets	19950
a reward	19971
B , The DFR apparatus ,	19981
B	19981
The DFR apparatus	19984
the opening in the floor at 0.75 inches , as was used for all testing procedures	20027
the opening	20027
the floor at 0.75 inches , as was used for all testing procedures	20042
the floor	20042
0.75 inches , as was used for all testing procedures	20055
0.75 inches	20055
all testing procedures	20084
C , Graph showing the successful performance of the DFR task -LRB- expressed as percentages of total attempts -RRB- when tested before surgery .	20108
C	20108
Graph showing the successful performance of the DFR task -LRB- expressed as percentages of total attempts -RRB- when tested before surgery	20111
Graph	20111
the successful performance of the DFR task -LRB- expressed as percentages of total attempts -RRB- when tested before surgery	20125
the successful performance	20125
the DFR task -LRB- expressed as percentages of total attempts -RRB- when tested before surgery	20155
the DFR task	20155
percentages of total attempts	20182
percentages	20182
total attempts	20197
surgery	20232
inclusion in the study	20261
inclusion	20261
the study	20274
the rats in all of the groups	20285
the rats	20285
all of the groups	20297
all	20297
the groups	20304
the DFR task	20325
at least 90 %	20351
the trials	20367
D , Graph showing DFR success for each group after surgery -LRB- expressed as percentages of total attempts -RRB- .	20379
D	20379
Graph showing DFR success for each group after surgery -LRB- expressed as percentages of total attempts -RRB-	20382
Graph	20382
DFR success	20396
each group after surgery -LRB- expressed as percentages of total attempts -RRB-	20412
each group	20412
surgery	20429
percentages of total attempts	20451
percentages	20451
total attempts	20466
The sham group -LRB- 94.86 ± 0.86 % -RRB-	20483
sham group -LRB- 94.86 ± 0.86 % -RRB-	20487
sham	20487
group -LRB- 94.86 ± 0.86 % -RRB-	20492
group	20492
94.86 ± 0.86 %	20499
94.86	20499
0.86 %	20507
all of the other groups	20550
all	20550
the other groups	20557
There	20575
no significant difference in DFR success	20585
no significant difference	20585
DFR success	20614
the lesion -LRB- 38.38 ± 8.31 % -RRB- and vehicle -LRB- 42.41 ± 7.10 % -RRB- groups	20634
the lesion -LRB- 38.38 ± 8.31 % -RRB-	20634
the lesion	20634
38.38 ± 8.31 %	20646
38.38	20646
8.31 %	20654
vehicle -LRB- 42.41 ± 7.10 % -RRB- groups	20665
vehicle -LRB- 42.41 ± 7.10 % -RRB-	20665
vehicle	20665
42.41 ± 7.10 %	20674
42.41	20674
7.10 %	20682
groups	20689
both	20706
the MP group -LRB- 56.66 ± 5.63 % -RRB-	20746
the MP	20746
group -LRB- 56.66 ± 5.63 % -RRB-	20753
group	20753
56.66 ± 5.63 %	20760
56.66	20760
5.63 %	20768
Groups	20776
ECs , both alone -LRB- 71.84 ± 5.20 % -RRB- and in combination with MP -LRB- 78.26 ± 0668 % -RRB- , performed the DFR task significantly better than all other lesioned animals	20793
ECs	20793
both alone -LRB- 71.84 ± 5.20 % -RRB-	20798
both alone	20798
71.84 ± 5.20 %	20810
71.84	20810
5.20 %	20818
in combination with MP -LRB- 78.26 ± 0668 % -RRB- , performed the DFR task significantly better than all other lesioned animals	20829
combination	20832
MP -LRB- 78.26 ± 0668 % -RRB- , performed the DFR task significantly better than all other lesioned animals	20849
MP -LRB- 78.26 ± 0668 % -RRB-	20849
MP	20849
78.26 ± 0668 %	20853
78.26	20853
0668 %	20861
the DFR task	20879
all other lesioned animals	20918
these two groups	20955
each other	21010
Figure 2 .	21023
Figure	21023
2	21030
Fluorogold-labeled CST neurons .	21033
Fluorogold-labeled CST	21033
neurons	21056
These neurons , filled with the retrograde tracer Fluorogold ,	21065
These neurons	21065
the retrograde tracer Fluorogold	21092
the origin of the corticospinal axons that were severed in the spinal cord at C3	21130
the origin	21130
the corticospinal axons that were severed in the spinal cord at C3	21144
the corticospinal axons	21144
the spinal cord at C3	21189
the spinal cord	21189
C3	21208
Fluorogold	21212
the soma , axons , and dendrites of these neurons	21243
the soma	21243
axons	21253
dendrites of these neurons	21264
dendrites	21264
these neurons	21277
Scale bar , 50 µm .	21292
Scale bar	21292
50 µm	21303
Figure 3 .	21311
Figure	21311
3	21318
Data from 1 , 10 , and 19 mm caudal to the lesion .	21321
Data	21321
1 , 10 , and 19 mm caudal	21331
1	21331
10	21334
19 mm caudal	21342
the lesion	21358
Representative photomicrographs of axons from the lesion , vehicle , MP , EC , MP/EC , and sham groups at each of these three distances caudal to the lesion .	21370
Representative photomicrographs of axons from the lesion , vehicle , MP , EC , MP/EC , and sham groups at each of these three distances	21370
Representative photomicrographs	21370
axons from the lesion , vehicle , MP , EC , MP/EC , and sham groups	21405
axons	21405
the lesion , vehicle , MP , EC , MP/EC , and sham groups	21416
each of these three distances	21471
each	21471
these three distances	21479
the lesion	21511
Axons	21523
they	21545
BDT	21567
1 mm caudal to the lesion	21575
1 mm caudal	21575
the lesion	21590
there	21602
no significant difference between mean number of axons of the lesion -LRB- A ; 9.58 ± 5.53 -RRB- and vehicle -LRB- D ; 10.95 ± 3.25 -RRB- groups	21611
no significant difference	21611
mean number of axons of the lesion -LRB- A ; 9.58 ± 5.53 -RRB- and vehicle -LRB- D ; 10.95 ± 3.25 -RRB- groups	21645
mean number	21645
axons of the lesion -LRB- A ; 9.58 ± 5.53 -RRB- and vehicle -LRB- D ; 10.95 ± 3.25 -RRB- groups	21660
axons of the lesion -LRB- A ; 9.58 ± 5.53 -RRB-	21660
axons	21660
the lesion -LRB- A ; 9.58 ± 5.53 -RRB-	21669
the lesion	21669
A ; 9.58 ± 5.53	21681
A	21681
9.58 ± 5.53	21684
9.58	21684
5.53	21691
vehicle -LRB- D ; 10.95 ± 3.25 -RRB- groups	21701
vehicle	21701
D ; 10.95 ± 3.25	21710
D	21710
10.95 ± 3.25	21713
10.95 ±	21713
3.25	21721
groups	21727
there	21739
significantly more axons in the MP group -LRB- G ; 32.01 ± 3.41 -RRB-	21749
significantly more axons	21749
the MP group -LRB- G ; 32.01 ± 3.41 -RRB-	21777
the MP group	21777
G ; 32.01 ± 3.41	21791
G	21791
32.01 ± 3.41	21794
32.01	21794
3.41	21802
The EC group -LRB- J ; 43.57 ± 3.05 -RRB-	21809
The EC group	21809
J ; 43.57 ± 3.05	21823
J	21823
43.57 ± 3.05	21826
43.57	21826
3.05	21834
significantly more axons than the MP group	21844
significantly more axons	21844
the MP group	21874
the MP/EC group -LRB- M ; 55.99 ± 2.96 -RRB-	21892
the MP/EC group	21892
M ; 55.99 ± 2.96	21909
M	21909
55.99 ± 2.96	21912
55.99	21912
2.96	21920
significantly more axons than all other lesioned groups	21930
significantly more axons	21930
all other lesioned groups	21960
this distance only	21990
there	22010
no significant -LRB- Figure legend continues	22019
no significant	22019
Figure legend	22035
Figure legend	22062
difference between the MP/EC and sham -LRB- P ; 59.02 ± 4.01 -RRB- groups .	22088
difference	22088
the MP/EC and sham -LRB- P ; 59.02 ± 4.01 -RRB- groups	22107
the MP/EC	22107
sham -LRB- P ; 59.02 ± 4.01 -RRB- groups	22121
sham	22121
P ; 59.02 ± 4.01	22127
P	22127
59.02 ± 4.01	22130
59.02	22130
4.01	22138
groups	22144
10 mm distal to the lesion	22155
10 mm	22155
the lesion	22171
there	22183
no significant difference between the lesion -LRB- B ; 0.66 ± 0.59 -RRB- , vehicle -LRB- E ; 0.73 ± 0.73 -RRB- , andMP -LRB- H ; 5.85 ± 0.91 -RRB- groups	22192
no significant difference	22192
the lesion -LRB- B ; 0.66 ± 0.59 -RRB- , vehicle -LRB- E ; 0.73 ± 0.73 -RRB- , andMP -LRB- H ; 5.85 ± 0.91 -RRB- groups	22226
the lesion -LRB- B ; 0.66 ± 0.59 -RRB-	22226
the lesion	22226
B ; 0.66 ± 0.59	22238
B	22238
0.66 ± 0.59	22241
0.66	22241
0.59	22248
vehicle -LRB- E ; 0.73 ± 0.73 -RRB-	22255
vehicle	22255
E ; 0.73 ± 0.73	22264
E	22264
0.73 ± 0.73	22267
0.73	22267
0.73	22274
andMP -LRB- H ; 5.85 ± 0.91 -RRB- groups	22281
andMP	22281
H ; 5.85 ± 0.91	22288
H	22288
5.85 ± 0.91	22291
5.85	22291
0.91	22298
groups	22304
All three of these groups	22312
All three	22312
these groups	22325
significantly fewer axons than the EC group	22343
significantly fewer axons	22343
the EC group	22374
K ; 12.35 ± 2.57	22388
K	22388
12.35 ± 2.57	22391
12.35	22391
2.57	22399
the EC group	22410
significantly fewer axons than the MP/EC group -LRB- N ; 22.48 ± 6.00 -RRB-	22427
significantly fewer axons	22427
the MP/EC group	22458
N ; 22.48 ± 6.00	22475
N	22475
22.48 ± 6.00	22478
22.48	22478
6.00	22486
There	22493
significantly more axons in the sham group	22503
significantly more axons	22503
the sham group	22531
all the other groups at this distance -LRB- Q ; 53.26 ± 3.88 -RRB-	22554
all the other groups	22554
this distance -LRB- Q ; 53.26 ± 3.88 -RRB-	22578
this distance	22578
Q ; 53.26 ± 3.88	22593
Q	22593
53.26 ± 3.88	22596
53.26	22596
3.88	22604
19 mm , the lesion -LRB- C ; 0.02 ± 0.02 -RRB- , vehicle -LRB- F ; 0.04 ± 0.04 -RRB- , and MP -LRB- I ; 0.18 ± 0.03 -RRB-	22614
19 mm	22614
the lesion -LRB- C ; 0.02 ± 0.02 -RRB- , vehicle -LRB- F ; 0.04 ± 0.04 -RRB- , and MP -LRB- I ; 0.18 ± 0.03 -RRB-	22621
the lesion -LRB- C ; 0.02 ± 0.02 -RRB-	22621
the lesion	22621
C ; 0.02 ± 0.02	22633
C	22633
0.02 ± 0.02	22636
0.02	22636
0.02	22643
vehicle -LRB- F ; 0.04 ± 0.04 -RRB-	22650
vehicle	22650
F ; 0.04 ± 0.04	22659
F	22659
0.04 ± 0.04	22662
0.04	22662
0.04	22669
MP -LRB- I ; 0.18 ± 0.03 -RRB-	22680
MP	22680
I ; 0.18 ± 0.03	22683
I	22683
0.18 ± 0.03	22686
0.18	22686
0.03	22693
groups	22699
The EC -LRB- L ; 2.18 ± 0.16 -RRB- and MP/EC -LRB- O ; 2.23 ± 0.20 -RRB- groups	22745
The EC -LRB- L ; 2.18 ± 0.16 -RRB-	22745
The EC	22745
L ; 2.18 ± 0.16	22753
L	22753
2.18 ± 0.16	22756
2.18	22756
0.16	22763
MP/EC -LRB- O ; 2.23 ± 0.20 -RRB- groups	22773
MP/EC	22773
O ; 2.23 ± 0.20	22780
O	22780
2.23 ± 0.20	22783
2.23	22783
0.20	22790
groups	22796
significantly more axons than all other lesioned groups	22808
significantly more axons	22808
all other lesioned groups	22838
there	22869
no significant difference between these groups	22878
no significant difference	22878
these groups	22912
The sham group	22926
significantly more axons than all other groups at this distance -LRB- R ; 52.19 ± 2.96 -RRB-	22945
significantly more axons	22945
all other groups at this distance -LRB- R ; 52.19 ± 2.96 -RRB-	22975
all other groups	22975
this distance -LRB- R ; 52.19 ± 2.96 -RRB-	22995
this distance	22995
R ; 52.19 ± 2.96	23010
R	23010
52.19 ± 2.96	23013
52.19	23013
2.96	23021
Scale bar , 50 µm .	23028
Scale bar	23028
50 µm	23039
Figure 4 .	23047
Figure	23047
4	23054
Graphical and tabular presentation of the axonal data .	23057
Graphical and tabular presentation of the axonal data	23057
Graphical	23057
tabular presentation of the axonal data	23071
tabular presentation	23071
the axonal data	23095
Graphs of the mean number of axons for the lesion , vehicle , MP , EC , and MP/EC groups at 1 mm -LRB- A -RRB- , 10 mm -LRB- B -RRB- , and 19 mm -LRB- C -RRB- caudal to the lesion .	23112
Graphs of the mean number of axons for the lesion , vehicle , MP , EC , and MP/EC groups at 1 mm -LRB- A -RRB- , 10 mm -LRB- B -RRB- , and 19 mm -LRB- C -RRB-	23112
Graphs	23112
the mean number of axons for the lesion , vehicle , MP , EC , and MP/EC groups	23122
the mean number	23122
axons for the lesion , vehicle , MP , EC , and MP/EC groups	23141
axons	23141
the lesion , vehicle , MP , EC , and MP/EC groups	23151
1 mm -LRB- A -RRB- , 10 mm -LRB- B -RRB- , and 19 mm -LRB- C -RRB-	23200
1 mm -LRB- A -RRB-	23200
A	23206
10 mm -LRB- B -RRB-	23210
B	23217
19 mm -LRB- C -RRB-	23225
C	23232
caudal to the lesion	23235
caudal	23235
the lesion	23245
the axon means	23265
all distances relative to the axon means for the other groups	23295
all distances	23295
the axon	23321
the other groups	23340
the data for the sham group	23358
the data	23358
the sham group	23371
1 mm caudal	23420
the lesion -LRB- A -RRB-	23435
the lesion	23435
A	23447
The table -LRB- D -RRB-	23451
The table	23451
D	23462
the complete set of data	23488
the complete set	23488
data	23508
the axon	23517
the seven distances -LRB- 1 , 4 , 7 , 10 , 13 , 16 , and 19 mm -RRB- caudal to the lesion for the three control and three experimental groups used in this study	23536
the seven distances -LRB- 1 , 4 , 7 , 10 , 13 , 16 , and 19 mm -RRB- caudal to the lesion for the three control	23536
the seven distances -LRB- 1 , 4 , 7 , 10 , 13 , 16 , and 19 mm -RRB- caudal	23536
seven distances -LRB- 1 , 4 , 7 , 10 , 13 , 16 , and 19 mm -RRB-	23540
seven distances	23540
1 , 4 , 7 , 10 , 13 , 16 , and 19 mm	23557
1	23557
4	23560
7	23563
10	23566
13	23570
16	23574
19 mm	23582
the lesion for the three control	23599
the lesion	23599
the three control	23614
three experimental groups used in this study	23636
three experimental groups	23636
this study	23670
Data	23682
mean ± SEM number of axons	23704
mean ± SEM number	23704
axons	23725
Figure 5 .	23733
Figure	23733
5	23740
ECs	23743
axons	23764
Photomicrographs of BDTlabeled CST axons -LRB- red -RRB-	23771
Photomicrographs of BDTlabeled CST axons	23771
Photomicrographs	23771
BDTlabeled CST axons	23791
red	23813
Cell Tracker green-labeled ECs	23832
Cell	23832
Tracker green-labeled ECs	23837
ECs in both the EC and MP/EC groups	23864
ECs	23864
both the EC and MP/EC groups	23871
the EC	23876
MP/EC groups	23887
all distances	23908
representative images	23927
1 mm -LRB- A and B , respectively -RRB- , 7 mm -LRB- C and D -RRB- , 13 mm -LRB- E and F -RRB- , and 19 mm -LRB- G and H -RRB- , the farthest distance analyzed	23964
1 mm -LRB- A and B , respectively -RRB- , 7 mm -LRB- C and D -RRB- , 13 mm -LRB- E and F -RRB- , and 19 mm -LRB- G and H -RRB-	23964
1 mm -LRB- A and B , respectively -RRB-	23964
A and B , respectively	23970
A and B	23970
7 mm -LRB- C and D -RRB-	23994
C and D	24000
C	24000
D	24006
13 mm -LRB- E and F -RRB-	24010
E and F	24017
E	24017
F	24023
19 mm -LRB- G and H -RRB-	24031
G and H	24038
G	24038
H	24044
the farthest distance analyzed	24048
the farthest distance	24048
Scale bar , 50 µm .	24080
Scale bar	24080
50 µm	24091
Immediate postoperative observations	24099
the week	24143
surgery	24158
all animals	24167
lack of bladder control , wound opening , and signs of infection	24197
lack	24197
bladder control , wound opening , and signs of infection	24205
bladder control	24205
wound opening	24222
signs of infection	24241
signs	24241
infection	24250
neurological deficits	24301
some animals	24327
a slight paresis and/or ataxia	24341
a slight paresis	24341
ataxia	24365
these symptoms	24387
2 weeks of surgery	24418
2 weeks	24418
surgery	24429
Functional recovery Rats	24438
surgery	24482
a DFR presurgery baseline	24503
This presurgical baseline	24530
all rats	24569
the DFR task	24618
differences in presurgical ability	24660
differences	24660
presurgical ability	24675
the postsurgical scores	24712
all rats	24737
the DFR task	24771
a success rate of at least 90 %	24787
a success rate	24787
at least 90 %	24805
the beginning of Materials and Methods	24831
the beginning	24831
Materials and Methods	24848
Materials	24848
Methods	24862
two rats	24871
this level	24899
the study	24945
All other rats	24956
the criterion	24975
inclusion in the study	25003
inclusion	25003
the study	25016
The presurgery DFR scores -LRB- Fig. 1C -RRB- for each group	25027
The presurgery DFR scores -LRB- Fig. 1C -RRB-	25027
The presurgery DFR scores	25027
Fig. 1C	25054
each group	25067
sham , 95.95 ± 3.91 ; lesion , 95.19 ± 3.72 ; vehicle , 95.41 ± 4.11 ; MP , 95.20 ± 4.59 ; EC , 94.40 ± 3.47 ; and MP/EC , 93.97 ± 3.89	25095
sham	25095
95.95 ± 3.91 ; lesion , 95.19 ± 3.72 ; vehicle , 95.41 ± 4.11 ; MP , 95.20 ± 4.59 ; EC , 94.40 ± 3.47 ; and MP/EC , 93.97 ± 3.89	25101
95.95 ± 3.91	25101
95.95	25101
3.91	25109
lesion , 95.19 ± 3.72	25115
lesion	25115
95.19 ± 3.72	25123
95.19	25123
3.72	25131
vehicle , 95.41 ± 4.11	25137
vehicle	25137
95.41 ± 4.11	25146
95.41	25146
4.11	25154
MP , 95.20 ± 4.59	25160
MP	25160
95.20 ± 4.59	25164
95.20	25164
4.59	25172
EC , 94.40 ± 3.47	25178
EC	25178
94.40 ± 3.47	25182
94.40	25182
3.47	25190
MP/EC , 93.97 ± 3.89	25200
MP/EC	25200
93.97 ± 3.89	25207
93.97	25207
3.89	25215
the sixth week after injury	25228
the sixth week	25228
injury	25249
rats	25257
their ability to perform the DFR task -LRB- Fig. 1D -RRB-	25284
the DFR task -LRB- Fig. 1D -RRB-	25309
the DFR task	25309
Fig. 1D	25323
this functional test	25339
the sham animals	25361
the DFR task	25388
well postsurgically -LRB- 94.86 ± 3.86 % -RRB- as they did presurgically	25404
well postsurgically -LRB- 94.86 ± 3.86 % -RRB-	25404
well postsurgically	25404
94.86 ± 3.86 %	25425
94.86	25425
3.86 %	25433
they	25443
This finding	25467
only the lesion , and no other portion of the surgical procedure ,	25498
only the lesion	25498
no other portion of the surgical procedure	25519
no other portion	25519
the surgical procedure	25539
the rats ' abilities to perform the DFR task	25573
the rats '	25573
the DFR task	25604
the sham group	25637
a significant functional deficit	25653
all rats that were lesioned	25699
all rats	25699
their treatment group	25742
this functional deficit in performing the DFR task	25774
this functional deficit	25774
the DFR task	25812
the same	25833
all of the experimental groups	25849
all	25849
the experimental groups	25856
The lesion and vehicle groups	25881
the most impaired of all of the groups	25916
the most impaired	25916
all of the groups	25937
all	25937
the groups	25944
surgery	25961
The lesion and vehicle groups	25970
the DFR task	26021
a success rate of only 38.38 ± 8.31 and 42.41	26039
a success rate	26039
only 38.38 ± 8.31 and 42.41	26057
only 38.38	26057
8.31 and 42.41	26070
7.10 %	26087
there	26108
no significant difference between these two groups	26118
no significant difference	26118
these two groups	26152
The MP group , with a success rate of 56.66 ± 5.63 % ,	26170
The MP group	26170
a success rate of 56.66 ±	26189
a success rate	26189
56.66 ±	26207
5.63 %	26215
the lesion and vehicle groups	26258
The EC group	26289
the DFR task significantly better	26312
the DFR task	26312
the lesion , vehicle , and MP groups	26351
the lesion	26351
vehicle	26363
MP groups	26376
a success rate of 71.84 ± 5.20 %	26392
a success rate	26392
71.84 ± 5.20 %	26410
71.84 ±	26410
5.20 %	26418
the EC group	26430
the MP/EC group , with a success rate of 78.26 ± 6.68 % ,	26444
the MP/EC group	26444
a success rate of 78.26 ±	26466
a success rate	26466
78.26 ±	26484
6.68 %	26492
the DFR task significantly better	26509
the DFR task	26509
the lesion , vehicle , and MP groups	26548
the lesion	26548
vehicle	26560
MP groups	26573
the group that received the combination treatment of ECs and MP	26593
the group	26593
the combination treatment of ECs and MP	26617
the combination treatment	26617
ECs and MP	26646
the DFR task	26667
a higher success rate -LRB- 78.26 % -RRB-	26685
a higher success rate	26685
78.26 %	26708
the group that received ECs alone -LRB- 71.84 % -RRB-	26721
the group	26721
ECs	26745
71.84 %	26756
this difference	26765
Histology and axonal counts Fluorogold-labeled neurons The primary motor cortex	26816
Histology	26816
axonal counts Fluorogold-labeled neurons The primary motor cortex	26830
axonal counts	26830
Fluorogold-labeled neurons	26844
The primary motor cortex	26871
all rats used in this study	26912
all rats	26912
this study	26929
All of the brains	26941
All	26941
the brains	26948
Fluorogold-labeled neurons	26969
layer V of the primary motor cortex	26999
layer V	26999
the primary motor cortex	27010
the dorsal CST axons	27052
the dorsal	27052
CST axons	27063
the lesioning procedure -LRB- Fig. 2 -RRB-	27096
the lesioning procedure	27096
Fig. 2	27121
all CST axons located in the dorsal funiculus	27138
all CST axons	27138
the dorsal funiculus	27163
surgery	27207
just those in the forelimb representation	27223
just those	27223
the forelimb representation	27237
Fluorogold-labeled neurons	27266
the primary motor cortex in layer V. Unlabeled pyramidal neurons were also found scattered throughout the primary motor cortex in layer V	27315
the primary motor cortex	27315
layer V. Unlabeled pyramidal neurons were also found scattered throughout the primary motor cortex in layer V	27343
layer V. Unlabeled	27343
pyramidal neurons	27362
the primary motor cortex in layer V	27417
the primary motor cortex	27417
layer V	27445
It	27454
these neurons	27474
uncrossed CST axons located in the ventral funiculus of the spinal cord	27502
uncrossed CST axons	27502
the ventral funiculus of the spinal cord	27533
the ventral funiculus	27533
the spinal cord	27558
The only exception to this labeling pattern	27575
The only exception	27575
this labeling pattern	27597
the brains of the rats that were in the sham group , whose brains had no Fluorogold label	27626
the brains	27626
the rats that were in the sham group , whose brains had no Fluorogold label	27640
the rats	27640
the sham group , whose brains had no Fluorogold label	27662
the sham group	27662
no Fluorogold label	27695
Biotin dextran tetramethylrhodamine-labeled axons All of the groups	27716
Biotin dextran	27716
tetramethylrhodamine-labeled axons	27731
All of the groups	27766
All	27766
the groups	27773
some CST axonal growth caudal	27791
the lesion	27824
regrowth	27845
all of the animals in every group	27883
all	27883
the animals in every group	27890
the animals	27890
every group	27905
There	27918
three rats -LRB- two lesion and one vehicle -RRB- that did not have any BDT-labeled CST axons caudal to the lesion site	27929
three rats	27929
two lesion and one vehicle	27941
two lesion	27941
one vehicle	27956
any BDT-labeled CST axons caudal to the lesion site	27987
any BDT-labeled CST	27987
axons	28007
the lesion site	28023
the lack of labeled CST axons	28055
the lack	28055
labeled CST axons	28067
a problem with the BDT or the labeling technique	28105
a problem	28105
the BDT or the labeling technique	28120
the BDT	28120
the labeling technique	28131
the spinal cords of these three rats	28155
the spinal cords	28155
these three rats	28175
rostral	28206
the lesion	28217
All three	28229
BDT-labeled CST axons	28258
the injury site	28292
all groups	28312
CST axons	28324
course	28348
the white matter of the dorsal funiculus	28358
the white matter	28358
the dorsal funiculus	28378
occasion	28407
the gray matter	28436
these CST axons	28458
the gray matter	28491
they	28508
the border between the gray and white matter	28527
the border	28527
the gray and white matter	28546
those rats that received EC transplants	28576
those rats	28576
EC transplants	28601
ECs	28617
the spinal cord white matter	28654
they	28693
the spinal cord gray matter	28719
the ECs	28757
the length of the axons	28808
the length	28808
the axons	28822
the ECs	28833
all areas in which regrowing axons were seen	28855
all areas	28855
regrowing axons	28874
The tissue	28901
19 mm caudal	28931
the lesion	28947
ECs	28963
this distance and densities that qualitatively appeared to be similar to all distances analyzed at 4 mm caudal to the lesion and beyond	28983
this distance	28983
densities that qualitatively appeared to be similar to all distances analyzed at 4 mm caudal to the lesion and beyond	29001
densities	29001
all distances analyzed at 4 mm caudal to the lesion and beyond	29056
all distances	29056
4 mm caudal to the lesion and beyond	29082
4 mm caudal	29082
the lesion	29097
ECs	29129
1 mm caudal	29164
the lesion	29179
The number of BDT-labeled axons present	29191
The number	29191
BDT-labeled axons present	29205
BDT-labeled axons	29205
all control and experimental groups	29248
all control	29248
experimental groups	29264
1 , 4 , 7 , 10 , 13 , 16 , and 19 mm caudal	29287
1	29287
4	29290
7	29293
10	29296
13	29300
16	29304
19 mm caudal	29312
the lesion site	29328
A representative photomicrograph from each group -LRB- Fig. 3 -RRB- and a graph comparing the means from the groups -LRB- Fig. 4A -- C -RRB-	29345
A representative photomicrograph	29345
each group -LRB- Fig. 3 -RRB- and a graph comparing the means from the groups -LRB- Fig. 4A -- C -RRB-	29383
each group -LRB- Fig. 3 -RRB-	29383
each group	29383
Fig. 3	29395
a graph comparing the means from the groups -LRB- Fig. 4A -- C -RRB-	29407
a graph	29407
the means	29425
the groups -LRB- Fig. 4A -- C -RRB-	29440
the groups	29440
Fig. 4A -- C	29452
Fig. 4A	29452
C	29460
1 , 10 , and 19 mm	29481
1	29481
10	29484
19 mm	29492
Figure 4D	29512
the mean number of labeled axons for each group at all of the distances examined	29525
the mean number	29525
axons for each group	29552
axons	29552
each group	29562
all of the distances examined	29576
all	29576
the distances examined	29583
the distances	29583
Differences between the means of groups	29607
Differences	29607
the means of groups	29627
the means	29627
groups	29640
most of the graphs	29678
most	29678
the graphs	29686
the sham group data	29702
the means for the sham group	29744
the means	29744
the sham group	29758
the means of all the other groups	29795
the means	29795
all the other groups	29808
1 mm	29840
the data for the sham group	29857
the data	29857
the sham group	29870
Figure 4A , which presents the data for the groups at 1 mm caudal to the lesion	29921
Figure 4A	29921
the data for the groups	29947
the data	29947
the groups	29960
1 mm caudal to the lesion	29974
1 mm caudal	29974
the lesion	29989
all of the examined intervals , the mean number of axons were highest in the sham group -LRB- Fig. 4D -RRB- , and , at each distance examined	30012
all	30012
the examined intervals , the mean number of axons were highest in the sham group -LRB- Fig. 4D -RRB- , and , at each distance examined	30019
the	30019
intervals	30032
the mean number of axons	30043
the mean number	30043
axons	30062
highest in the sham group -LRB- Fig. 4D -RRB-	30073
highest	30073
the sham group -LRB- Fig. 4D -RRB-	30084
the sham group	30084
Fig. 4D	30100
each distance examined	30118
each distance	30118
the mean number of labeled axons in the sham group	30142
the mean number	30142
labeled axons in the sham group	30161
labeled axons	30161
the sham group	30178
all other groups	30226
one exception , which is noted below	30249
one exception	30249
the functional data reported above	30297
the functional data	30297
there	30333
no significant difference between the means of the lesion and vehicle groups at any distance examined -LRB- Fig. 4 -RRB-	30343
no significant difference	30343
the means of the lesion and vehicle groups at any distance examined -LRB- Fig. 4 -RRB-	30377
the means	30377
the lesion and vehicle groups at any distance examined -LRB- Fig. 4 -RRB-	30390
the lesion and vehicle groups	30390
any distance examined	30423
any distance	30423
Fig. 4	30446
these two groups	30458
axons	30476
only a short distance caudal	30493
the injury -LRB- Fig. 4A -RRB-	30525
the injury	30525
Fig. 4A	30537
10 mm distal to the lesion -LRB- Fig. 4B -RRB- to the farthest distance examined -LRB- Fig. 4C -RRB-	30555
10 mm	30555
the lesion -LRB- Fig. 4B -RRB- to the farthest distance examined -LRB- Fig. 4C -RRB-	30571
the lesion -LRB- Fig. 4B -RRB-	30571
the lesion	30571
Fig. 4B	30583
the farthest distance examined	30595
the farthest distance	30595
Fig. 4C	30627
all of the tissue	30637
all	30637
the tissue	30644
axons in both the lesion -LRB- Figs. 3A -- C , 4D -RRB- and vehicle -LRB- Figs. 3D -- F , 4D -RRB- groups	30679
axons in both the lesion -LRB- Figs. 3A -- C , 4D -RRB-	30679
axons	30679
both the lesion -LRB- Figs. 3A -- C , 4D -RRB-	30688
both the lesion	30688
Figs. 3A	30705
C , 4D	30714
C	30714
4D	30717
vehicle -LRB- Figs. 3D -- F , 4D -RRB- groups	30725
vehicle	30725
Figs. 3D	30734
F , 4D	30743
F	30743
4D	30746
groups	30750
the MP group	30761
axons	30775
7 mm	30804
10 mm	30822
the MP	30840
very few labeled axons -LRB- Figs. 3G -- I , 4D -RRB-	30851
very few	30851
axons -LRB- Figs. 3G -- I , 4D -RRB-	30868
axons	30868
Figs. 3G	30875
I , 4D	30884
I	30884
4D	30887
the MP group	30921
significantly more axons	30938
the lesion and vehicle groups	30968
1 , 4 , and 7 mm -LRB- Fig. 4A , D -RRB-	31001
1	31001
4	31004
7 mm	31011
Fig. 4A , D	31017
Fig. 4A	31017
D	31025
10 , 13 , 16 , and 19 mm	31041
10	31041
13	31045
16	31049
19 mm	31057
no significant differences	31064
the means of these three groups -LRB- Fig. 4B -- D -RRB-	31108
the means	31108
these three groups -LRB- Fig. 4B -- D -RRB-	31121
these three groups	31121
Fig. 4B -- D	31141
Fig. 4B	31141
D	31149
the photomicrographs of the tissue	31166
the photomicrographs	31166
the tissue	31190
the EC group -LRB- Fig. 3J -- L -RRB-	31206
the EC group	31206
Fig. 3J -- L	31220
Fig. 3J	31220
L	31228
it	31232
this group	31252
many more labeled axons than the lesion -LRB- Fig. 3A -- C -RRB- , vehicle -LRB- Fig. 3D -- F -RRB- , or MP -LRB- Fig. 3G -- I -RRB- groups	31267
many more labeled axons than the lesion -LRB- Fig. 3A -- C -RRB- , vehicle -LRB- Fig. 3D -- F -RRB- , or MP -LRB- Fig. 3G -- I -RRB-	31267
more labeled axons	31272
the lesion	31296
Fig. 3A -- C	31308
Fig. 3A	31308
C	31316
Fig. 3D -- F	31329
Fig. 3D	31329
F	31337
Fig. 3G -- I	31348
Fig. 3G	31348
I	31356
groups	31359
the number of labeled axons	31376
the number	31376
labeled axons	31390
proportion to distance caudal	31417
proportion	31417
distance caudal	31431
the injury -LRB- Fig. 4D -RRB-	31450
the injury	31450
Fig. 4D	31462
axons	31472
the farthest distance analyzed -LRB- Fig. 3L -RRB-	31499
the farthest distance	31499
Fig. 3L	31531
all tissue examined in the EC group	31544
all tissue	31544
the EC group	31567
Cell Tracker	31581
ECs	31607
the areas in which regrowing axons were located -LRB- Fig. 5 -RRB-	31625
the areas	31625
regrowing axons	31644
Fig. 5	31674
Analysis of the data	31683
Analysis	31683
the data	31695
the lesion , vehicle , and MP groups	31737
the lesion	31737
vehicle	31749
MP groups	31762
the EC group	31773
significantly more axons	31790
all distances examined -LRB- Fig. 4 -RRB-	31818
all distances	31818
Fig. 4	31842
These data	31851
the functional findings , which demonstrated that the rats receiving ECs regained significantly more CST function than the lesion , vehicle , and MP groups	31870
the functional findings	31870
the rats receiving ECs	31919
the rats	31919
ECs	31938
significantly more CST function	31951
the lesion , vehicle , and MP groups	31988
the lesion	31988
vehicle	32000
MP groups	32013
1 mm distal to the injury	32027
1 mm	32027
the injury	32042
the mean of theMP/EC group	32054
the mean	32054
theMP/EC group	32066
the rats in the sham control group -LRB- Figs. 3A , P , 4A , D -RRB-	32118
the rats	32118
the sham control group -LRB- Figs. 3A , P , 4A , D -RRB-	32130
the sham control group	32130
Figs. 3A	32154
P , 4A , D	32163
1 mm	32179
the sham group	32185
significantly more axons	32204
the MP/EC group -LRB- Figs. 3M -- R , 4 -RRB-	32234
the MP/EC group	32234
Figs. 3M -- R , 4	32251
Figs. 3M	32251
R , 4	32260
R	32260
the EC group	32275
the number of labeled axons in the MP/EC group	32289
the number	32289
labeled axons in the MP/EC group	32303
labeled axons	32303
the MP/EC group	32320
distance	32349
the lesion increased -LRB- Fig. 3M -- O , 4D -RRB-	32363
the lesion	32363
Fig. 3M -- O , 4D	32385
Fig. 3M	32385
O , 4D	32393
O	32393
4D	32396
axons	32405
19 mm -LRB- Fig. 3O -RRB-	32434
19 mm	32434
Fig. 3O	32441
the EC group	32457
the MP/EC group	32471
ECs that were visible throughout the regions in which axons were found -LRB- Fig. 5 -RRB-	32497
ECs	32497
the regions in which axons were found -LRB- Fig. 5 -RRB-	32530
the regions	32530
axons	32551
Fig. 5	32569
Statistical analysis	32578
the MP/EC group	32613
significantly more axons	32633
the lesion , vehicle , and MP groups	32663
the lesion	32663
vehicle	32675
MP groups	32688
all distances examined -LRB- Fig. 4 -RRB- , which agrees with the functional findings presented above	32701
all distances examined -LRB- Fig. 4 -RRB-	32701
all distances examined	32701
all distances	32701
Fig. 4	32725
the functional findings presented above	32752
the functional findings	32752
the means from the group that received the combined treatment were compared with the means from the group that received only ECs , significant differences in results	32798
the means	32798
the group that received the combined treatment were compared with the means from the group that received only ECs , significant differences in results	32813
the group	32813
the combined treatment	32837
the means	32879
the group that received only ECs , significant differences in results	32894
the group	32894
only ECs , significant differences in results	32918
only ECs	32918
significant differences in results	32928
significant differences	32928
results	32955
most distances	32975
the injury -LRB- Fig. 4 -RRB-	33000
the injury	33000
Fig. 4	33012
Analysis of the data from 1 , 4 , 7 , 10 , and 13 mm	33021
Analysis	33021
the data from 1 , 4 , 7 , 10 , and 13 mm	33033
the data	33033
1 , 4 , 7 , 10 , and 13 mm	33047
1	33047
4	33050
7	33053
10	33056
13 mm	33064
the MP/EC group	33088
significantly more axons	33108
the EC group -LRB- Fig. 4A , B , D -RRB-	33138
the EC group	33138
Fig. 4A	33152
B	33160
D	33162
no significant differences between the means of these two groups	33175
no significant differences	33175
the means of these two groups	33210
the means	33210
these two groups	33223
16 and 19 mm caudal	33254
16	33254
19 mm caudal	33261
the lesion -LRB- Fig. 4C , D -RRB-	33277
the lesion	33277
Fig. 4C , D	33289
Fig. 4C	33289
D	33297
This lack of significant differences between the means of the EC and MP/EC groups at the farthest distances analyzed	33301
This lack	33301
significant differences between the means of the EC and MP/EC groups at the farthest distances analyzed	33314
significant differences	33314
the means of the EC and MP/EC groups at the farthest distances analyzed	33346
the means	33346
the EC and MP/EC groups at the farthest distances analyzed	33359
the EC and MP/EC groups	33359
the farthest distances analyzed	33386
the farthest distances	33386
the lack of a significant difference between the DFR performance of these two groups	33430
the lack	33430
a significant difference between the DFR performance of these two groups	33442
a significant difference	33442
the DFR performance of these two groups	33475
the DFR performance	33475
these two groups	33498
functional differences	33540
a longer recovery period	33568
DISCUSSION	33595
there	33617
no treatment regimen available to restore sensory and motor function after debilitating SCI in humans	33626
no treatment regimen	33626
sensory and motor function	33668
SCI in humans	33714
SCI	33714
humans	33721
progress	33738
animal research	33764
Numerous treatment strategies	33781
damaged axons	33844
SCI in rats -LRB- David and Aguayo , 1981 ; Goldberg and Bernstein , 1987 ; Schnell and Schwab , 1993 ; Joosten et al. , 1995 ; Xu et al. , 1995 ; Chen et al. , 1996 ; Kalderon and Fuks , 1996 ; Bregman et al. , 1997 ; Guest et al. , 1997 ; Oudega et al. , 1997 ; Ye and Houle , 1997 ; Ramon-Cueto et al. , 1998 -RRB-	33864
SCI	33864
rats -LRB- David and Aguayo , 1981 ; Goldberg and Bernstein , 1987 ; Schnell and Schwab , 1993 ; Joosten et al. , 1995 ; Xu et al. , 1995 ; Chen et al. , 1996 ; Kalderon and Fuks , 1996 ; Bregman et al. , 1997 ; Guest et al. , 1997 ; Oudega et al. , 1997 ; Ye and Houle , 1997 ; Ramon-Cueto et al. , 1998 -RRB-	33871
rats	33871
David and Aguayo , 1981 ; Goldberg and Bernstein , 1987 ; Schnell and Schwab , 1993 ; Joosten et al. , 1995 ; Xu et al. , 1995 ; Chen et al. , 1996 ; Kalderon and Fuks , 1996 ; Bregman et al. , 1997 ; Guest et al. , 1997 ; Oudega et al. , 1997 ; Ye and Houle , 1997 ; Ramon-Cueto et al. , 1998	33877
David and Aguayo	33877
1981 ; Goldberg and Bernstein , 1987 ; Schnell and Schwab , 1993 ; Joosten et al. , 1995 ; Xu et al. , 1995 ; Chen et al. , 1996 ; Kalderon and Fuks , 1996 ; Bregman et al. , 1997 ; Guest et al. , 1997 ; Oudega et al. , 1997 ; Ye and Houle , 1997 ; Ramon-Cueto et al.	33895
1981	33895
Goldberg and Bernstein , 1987 ; Schnell and Schwab , 1993 ; Joosten et al. , 1995 ; Xu et al. , 1995 ; Chen et al. , 1996 ; Kalderon and Fuks , 1996 ; Bregman et al. , 1997 ; Guest et al. , 1997 ; Oudega et al. , 1997 ; Ye and Houle , 1997 ; Ramon-Cueto et al.	33901
Goldberg and Bernstein , 1987	33901
Goldberg and Bernstein	33901
1987	33925
Schnell and Schwab , 1993	33931
Schnell and Schwab	33931
1993	33951
Joosten et al. , 1995	33957
Joosten	33957
et al. , 1995	33965
et al.	33965
1995	33973
Xu et al. , 1995	33979
Xu	33979
et al. , 1995	33982
et al.	33982
1995	33990
Chen et al. , 1996	33996
Chen	33996
et al. , 1996	34001
et al.	34001
1996	34009
Kalderon and Fuks , 1996	34015
Kalderon and Fuks	34015
1996	34034
Bregman et al. , 1997	34040
Bregman	34040
et al. , 1997	34048
et al.	34048
1997	34056
Guest et al. , 1997	34062
Guest	34062
et al. , 1997	34068
et al.	34068
1997	34076
Oudega et al. , 1997	34082
Oudega	34082
et al. , 1997	34089
et al.	34089
1997	34097
Ye and Houle , 1997	34103
Ye	34103
Houle , 1997	34110
Houle	34110
1997	34117
Ramon-Cueto et al.	34123
Ramon-Cueto	34123
et al.	34135
1998	34143
these strategies	34156
the transplantation of various cell types , including fetal cells -LRB- Kunkel-Bagden and Bregman , 1990 ; Bernstein-Goral and Bregman , 1997 ; Mori et al. , 1997 ; Bregman et al. , 1998 ; Diener and Bregman , 1998a ; McDonald , 1999 -RRB- and Schwann cells -LRB- Kuhlengel et al. , 1990 ; Li and Raisman , 1994 ; Xu et al. , 1995 ; Chen et al. , 1996 ; Martin et al. , 1996 ; Guest et al. , 1997 -RRB-	34177
the transplantation	34177
various cell types	34200
fetal cells -LRB- Kunkel-Bagden and Bregman , 1990 ; Bernstein-Goral and Bregman , 1997 ; Mori et al. , 1997 ; Bregman et al. , 1998 ; Diener and Bregman , 1998a ; McDonald , 1999 -RRB- and Schwann cells -LRB- Kuhlengel et al. , 1990 ; Li and Raisman , 1994 ; Xu et al. , 1995 ; Chen et al. , 1996 ; Martin et al. , 1996 ; Guest et al. , 1997 -RRB-	34230
fetal cells	34230
Kunkel-Bagden and Bregman	34243
Kunkel-Bagden	34243
Bregman	34261
1990 ; Bernstein-Goral and Bregman , 1997 ; Mori et al. , 1997 ; Bregman et al. , 1998 ; Diener and Bregman , 1998a ; McDonald , 1999	34270
1990	34270
Bernstein-Goral and Bregman , 1997 ; Mori et al. , 1997 ; Bregman et al. , 1998 ; Diener and Bregman , 1998a ; McDonald , 1999	34276
Bernstein-Goral and Bregman , 1997	34276
Bernstein-Goral and Bregman	34276
1997	34305
Mori et al. , 1997	34311
Mori	34311
et al. , 1997	34316
et al.	34316
1997	34324
Bregman et al. , 1998	34330
Bregman	34330
et al. , 1998	34338
et al.	34338
1998	34346
Diener and Bregman , 1998a	34352
Diener and Bregman	34352
1998a	34372
McDonald , 1999	34379
McDonald	34379
1999	34389
Schwann cells	34399
Kuhlengel et al. , 1990 ; Li and Raisman , 1994 ; Xu et al. , 1995 ; Chen et al. , 1996 ; Martin et al. , 1996 ; Guest et al. , 1997	34414
Kuhlengel	34414
et al. , 1990 ; Li and Raisman , 1994 ; Xu et al. , 1995 ; Chen et al. , 1996 ; Martin et al. , 1996 ; Guest et al. , 1997	34424
et al. , 1990	34424
et al.	34424
1990	34432
Li and Raisman , 1994	34438
Li and Raisman	34438
1994	34454
Xu et al. , 1995	34460
Xu	34460
et al. , 1995	34463
et al.	34463
1995	34471
Chen et al. , 1996	34477
Chen	34477
et al. , 1996	34482
et al.	34482
1996	34490
Martin et al. , 1996	34496
Martin	34496
et al. , 1996	34503
et al.	34503
1996	34511
Guest et al. , 1997	34517
Guest	34517
et al. , 1997	34523
et al.	34523
1997	34531
Fetal spinal cord transplants	34538
the regrowth of CST , raphespinal , and rubrospinal axons -LRB- Diener and Bregman , 1998b -RRB-	34595
the regrowth	34595
CST , raphespinal , and rubrospinal axons -LRB- Diener and Bregman , 1998b -RRB-	34611
CST	34611
raphespinal	34616
rubrospinal axons	34633
Diener and Bregman	34652
1998b	34672
functional recovery	34699
injuries to the neonatal spinal cord -LRB- Diener and Bregman , 1998a -RRB-	34725
injuries	34725
the neonatal spinal cord -LRB- Diener and Bregman , 1998a -RRB-	34737
the neonatal spinal cord	34737
Diener and Bregman	34763
1998a	34783
The transplantation of murine embryonic stem cells into lesioned adult rat spinal cords	34791
The transplantation	34791
murine embryonic stem cells into lesioned adult rat spinal cords	34814
murine embryonic stem cells	34814
lesioned adult rat spinal cords	34847
enhanced weight bearing and coordination of hindlimbs -LRB- McDonald , 1999 -RRB-	34895
enhanced weight bearing	34895
coordination of hindlimbs -LRB- McDonald , 1999 -RRB-	34923
coordination	34923
hindlimbs -LRB- McDonald , 1999 -RRB-	34939
hindlimbs	34939
McDonald , 1999	34950
McDonald	34950
1999	34960
there	34976
a number of ethical issues surrounding the use of embryonic tissues that must be resolved before its use in a clinical setting	34986
a number	34986
ethical issues surrounding the use of embryonic tissues that must be resolved before its use in a clinical setting	34998
ethical issues	34998
the use of embryonic tissues that must be resolved before its use in a clinical setting	35025
the use	35025
embryonic tissues	35036
its use in a clinical setting	35083
its use	35083
a clinical setting	35094
Schwann cells	35114
regeneration	35160
SCI	35179
Schwann cells	35184
lesioning , resulting in reduced gliosis ,	35271
lesioning	35271
reduced gliosis	35295
Schwann cell survival	35321
regeneration of axons -LRB- Martin et al. , 1996 -RRB-	35357
regeneration	35357
axons -LRB- Martin et al. , 1996 -RRB-	35373
axons	35373
Martin	35380
et al. , 1996	35387
et al.	35387
1996	35395
Schwann cells	35415
-LRB- Li and Raisman , 1994 -RRB- , regrowth	35472
Li and Raisman	35473
1994	35489
the lesion -LRB- Xu et al. , 1997 -RRB-	35510
the lesion	35510
Xu	35522
et al. , 1997	35525
et al.	35525
1997	35533
combination with methylprednisolone , the regrowth of axons	35558
combination	35558
methylprednisolone , the regrowth of axons	35575
methylprednisolone	35575
the regrowth of axons	35595
the regrowth	35595
axons	35611
the lesion	35624
the host spinal cord	35640
modest functional improvement -LRB- Guest et al. , 1997 -RRB-	35673
modest functional improvement	35673
Guest	35704
et al. , 1997	35710
et al.	35710
1997	35718
transplanted Schwann cells	35734
axonal regrowth	35771
function	35799
Schwann cells	35809
the CNS	35845
A number	35854
studies have shown that Schwann cells have a poor survivability rate in the presence of astrocytes	35868
studies	35868
Schwann cells	35892
a poor survivability rate in the presence of astrocytes	35911
a poor survivability rate	35911
the presence of astrocytes	35940
the presence	35940
astrocytes	35956
their ability to remyelinate	35972
their ability	35972
remyelinate	35989
Franklin and Blakemore , 1993 ; Iwaniuk et al. , 1999	36016
Franklin and Blakemore	36016
1993 ; Iwaniuk et al.	36040
1993	36040
Iwaniuk et al.	36046
Iwaniuk	36046
et al.	36054
1999	36062
an astrocyte-free environment	36072
Schwann cell remyelination	36103
Duncan et al. , 1988 ; Shields et al. , 2000	36154
Duncan	36154
et al. , 1988 ; Shields et al. , 2000	36161
et al. , 1988	36161
et al.	36161
1988	36169
Shields et al. , 2000	36175
Shields	36175
et al. , 2000	36183
et al.	36183
2000	36191
This	36198
because	36206
Schwann cells transplanted into the CNS	36224
Schwann cells	36224
the CNS	36256
CNS axon regeneration	36289
Schwann cells	36312
astrocytes , a primary component of CNS lesion sites -LRB- Lakatos et al. , 2000 -RRB-	36353
astrocytes	36353
a primary component of CNS lesion sites -LRB- Lakatos et al. , 2000 -RRB-	36365
a primary component	36365
CNS lesion sites -LRB- Lakatos et al. , 2000 -RRB-	36388
CNS lesion sites	36388
Lakatos	36406
et al. , 2000	36414
et al.	36414
2000	36422
The ideal candidate for CNS transplantation	36429
The ideal candidate	36429
CNS transplantation	36453
a cell type that endogenously exists in the CNS and is therefore able to thrive in the CNS environment , as well as promote regeneration and remyelination	36480
a cell type	36480
the CNS	36520
the CNS environment	36563
regeneration and remyelination	36603
A cell type that meets these criteria	36635
A cell type	36635
these criteria	36658
the EC -LRB- Franklin and Barnett , 1997 ; Ramon-Cueto and Avila , 1998 ; Bartolomei and Greer , 2000 ; Lakatos et al. , 2000 -RRB- , shown recently to promote regeneration after SCI	36676
the EC -LRB- Franklin and Barnett , 1997 ; Ramon-Cueto and Avila , 1998 ; Bartolomei and Greer , 2000 ; Lakatos et al. , 2000 -RRB-	36676
the EC	36676
Franklin and Barnett , 1997 ; Ramon-Cueto and Avila , 1998 ; Bartolomei and Greer , 2000 ; Lakatos et al. , 2000	36684
Franklin and Barnett	36684
1997 ; Ramon-Cueto and Avila , 1998 ; Bartolomei and Greer , 2000 ; Lakatos et al.	36706
1997	36706
Ramon-Cueto and Avila , 1998 ; Bartolomei and Greer , 2000 ; Lakatos et al.	36712
Ramon-Cueto and Avila , 1998	36712
Ramon-Cueto and Avila	36712
1998	36735
Bartolomei and Greer , 2000	36741
Bartolomei and Greer	36741
2000	36763
Lakatos et al.	36769
Lakatos	36769
et al.	36777
2000	36785
regeneration	36818
SCI	36837
Investigators	36842
previously the ability of ECs	36870
previously the ability	36870
ECs	36896
axonal regeneration	36911
SCI -LRB- Li et al. , 1997 , 1998 ; Imaizumi et al. , 2000 ; Ramon-Cueto et al. , 2000 ; Lu et al. , 2001 -RRB-	36937
SCI	36937
Li	36942
et al. , 1997 , 1998 ; Imaizumi et al. , 2000 ; Ramon-Cueto et al. , 2000 ; Lu et al. , 2001	36945
et al.	36945
1997 , 1998 ; Imaizumi et al. , 2000 ; Ramon-Cueto et al. , 2000 ; Lu et al.	36953
1997 , 1998	36953
1997	36953
1998	36959
Imaizumi et al. , 2000	36965
Imaizumi	36965
et al. , 2000	36974
et al.	36974
2000	36982
Ramon-Cueto et al. , 2000	36988
Ramon-Cueto	36988
et al. , 2000	37000
et al.	37000
2000	37008
Lu et al.	37014
Lu	37014
et al.	37017
2001	37025
Our results	37032
data that has been reported previously regarding the ability of ECs	37052
data	37052
the ability of ECs	37101
the ability	37101
ECs	37116
axonal regeneration and functional recovery	37131
regeneration	37138
our study	37182
previous research by Li et al. -LRB- 1998 -RRB- and Ramon-Cueto et al. -LRB- 2000 -RRB-	37193
previous research	37193
Li et al. -LRB- 1998 -RRB- and Ramon-Cueto et al. -LRB- 2000 -RRB-	37214
Li et al. -LRB- 1998 -RRB-	37214
Li	37214
et al. -LRB- 1998 -RRB-	37217
et al.	37217
1998	37225
Ramon-Cueto et al. -LRB- 2000 -RRB-	37235
Ramon-Cueto	37235
et al. -LRB- 2000 -RRB-	37247
et al.	37247
2000	37255
the transplanted ECs	37267
the regrowth of CST axons grown through the lesioned site	37297
the regrowth	37297
CST axons grown through the lesioned site	37313
CST axons	37313
the lesioned site	37337
ECs	37369
recovery -LRB- Li et al. , 1997 ; Ramon - Cueto et al. , 2000 -RRB- , a finding that our data supports	37430
recovery	37430
Li	37440
et al. , 1997 ; Ramon - Cueto et al. , 2000	37443
et al.	37443
1997 ; Ramon - Cueto et al.	37451
1997 ; Ramon	37451
1997	37451
Ramon	37457
Cueto et al.	37464
Cueto	37464
et al.	37470
2000	37478
a finding that our data supports	37485
a finding	37485
our data	37500
The ability of ECs	37519
The ability	37519
ECs	37534
axonal regeneration when combined with other therapies has also been investigated -LRB- Ramon - Cueto et al. , 1998 -RRB-	37549
axonal regeneration when combined with other therapies has also been investigated	37549
axonal regeneration	37549
other therapies	37588
Ramon	37632
Cueto et al. , 1998	37639
Cueto	37639
et al.	37645
1998	37653
no one	37664
ECs in combination	37688
ECs	37688
combination	37695
MP	37712
The combined effects of these two therapies	37716
The combined effects	37716
these two therapies	37740
ECs	37796
use in humans	37825
use	37825
humans	37832
MP	37848
the only current treatment used clinically after an acute SCI -LRB- Bracken et al. , 1984 , 1990 , 1997 -RRB-	37854
the only current treatment	37854
an acute SCI -LRB- Bracken et al. , 1984 , 1990 , 1997 -RRB-	37903
an acute SCI	37903
Bracken	37917
et al. , 1984 , 1990 , 1997	37925
et al.	37925
1984	37933
1990	37939
1997	37945
the experiments described herein	37955
the experiments	37955
MP	37988
axonal regeneration	38012
functional recovery	38044
SCI	38070
untreated rats	38093
These improvements	38109
complete restoration of DFR function -LRB- 57 % -RRB-	38198
complete restoration	38198
DFR function -LRB- 57 % -RRB-	38222
DFR function	38222
57 %	38236
the limited distance that axons	38266
the limited distance	38266
7 mm	38325
contrast	38335
treatment with ECs	38345
treatment	38345
ECs	38360
axonal elongation	38376
the farthest distance analyzed caudal to the injury site -LRB- 19 mm -RRB- and the highest functional scores of all of the lesioned rats	38397
the farthest distance	38397
the injury site -LRB- 19 mm -RRB- and the highest functional scores of all of the lesioned rats	38438
the injury site -LRB- 19 mm -RRB-	38438
the injury site	38438
19 mm	38455
the highest functional scores of all of the lesioned rats	38466
the highest functional scores	38466
all of the lesioned rats	38499
all	38499
the lesioned rats	38506
This elongation	38525
ECs	38559
combination with MP	38588
combination	38588
MP	38605
more axons	38618
the MP/EC group	38643
the EC group at distances up to 13 mm caudal	38664
the EC group	38664
distances up to 13 mm caudal	38680
distances	38680
13 mm caudal	38696
the lesion	38712
this increase in axons	38724
this increase	38724
axons	38741
DFR performance of the MP/EC group -LRB- 78 % -RRB- when compared with the EC group -LRB- 72 % -RRB-	38787
DFR performance of the MP/EC group	38787
DFR performance	38787
the MP/EC group	38806
78 %	38823
the EC group -LRB- 72 % -RRB-	38847
the EC group	38847
72 %	38861
more time	38882
it	38893
the larger number of axons seen at shorter distances	38913
the larger number	38913
axons seen at shorter distances	38934
axons	38934
shorter distances	38948
more functional recovery in the MP/EC group	39001
more functional recovery	39001
the MP/EC group	39029
It	39046
note is that , when MP was used in combination with ECs , there was not a decrease in axonal regeneration or functional recovery , which was a potential concern	39072
note	39072
MP	39091
combination	39106
ECs	39123
there	39128
a decrease in axonal regeneration or functional recovery , which was a potential concern	39142
a decrease	39142
axonal regeneration or functional recovery , which was a potential concern	39156
axonal regeneration or functional recovery	39156
a potential concern	39210
Astrocytes	39231
the capacity to act as immune cells -LRB- Dong and Benveniste , 2001 -RRB-	39247
immune cells -LRB- Dong and Benveniste , 2001 -RRB-	39270
immune cells	39270
Dong and Benveniste	39284
2001	39305
MP	39316
the function of immune cells -LRB- Wahl et al. , 1975 ; Almawi et al. , 1991 -RRB-	39340
the function	39340
immune cells -LRB- Wahl et al. , 1975 ; Almawi et al. , 1991 -RRB-	39356
immune cells	39356
Wahl	39370
et al. , 1975 ; Almawi et al. , 1991	39375
et al.	39375
1975 ; Almawi et al.	39383
1975	39383
Almawi et al.	39389
Almawi	39389
et al.	39396
1991	39404
ECs	39419
phenotypic characteristics	39429
astrocytes	39461
it	39473
MP	39494
the function of ECs	39519
the function	39519
ECs	39535
a decreased effect in the MP/EC group	39553
a decreased effect	39553
the MP/EC group	39575
Investigation into the mechanisms of action of MP and ECs	39592
Investigation	39592
the mechanisms of action of MP and ECs	39611
the mechanisms	39611
action of MP and ECs	39629
action	39629
MP and ECs	39639
little insight	39656
the mechanism of action for MP	39695
the mechanism	39695
action for MP	39712
action	39712
MP	39723
the mechanism of action for ECs	39753
the mechanism	39753
action for ECs	39770
action	39770
ECs	39781
One mechanism to explain the action of MP	39820
One mechanism	39820
the action of MP	39845
the action	39845
MP	39859
binding of the glucocorticoid receptor , which mediates its anti-inflammatory properties	39873
binding	39873
the glucocorticoid receptor , which mediates its anti-inflammatory properties	39884
the glucocorticoid receptor	39884
its anti-inflammatory properties	39928
MP	39962
inflammatory processes induced after SCI -LRB- Hsu and Dimitrijevic , 1990 -RRB- , such as chemotaxis -LRB- Espersen et al. , 1989 -RRB- and the release of lysosomal enzymes -LRB- Schleimer et al. , 1989 -RRB-	39974
inflammatory processes	39974
SCI -LRB- Hsu and Dimitrijevic , 1990 -RRB- , such as chemotaxis -LRB- Espersen et al. , 1989 -RRB- and the release of lysosomal enzymes -LRB- Schleimer et al. , 1989 -RRB-	40011
SCI	40011
Hsu and Dimitrijevic	40016
1990	40038
chemotaxis -LRB- Espersen et al. , 1989 -RRB- and the release of lysosomal enzymes -LRB- Schleimer et al. , 1989 -RRB-	40053
chemotaxis -LRB- Espersen et al. , 1989 -RRB-	40053
chemotaxis	40053
Espersen	40065
et al. , 1989	40074
et al.	40074
1989	40082
the release of lysosomal enzymes -LRB- Schleimer et al. , 1989 -RRB-	40092
the release	40092
lysosomal enzymes -LRB- Schleimer et al. , 1989 -RRB-	40107
lysosomal enzymes	40107
Schleimer	40126
et al. , 1989	40136
et al.	40136
1989	40144
MP	40151
phospholipase A2 activity -LRB- Hirata et al. , 1980 -RRB- , which reduces the production of metabolites of the arachidonic acid cascade -LRB- Becker and Grasso , 1985 -RRB- thereby reducing the formation of free radicals -LRB- Hirata et al. , 1980 ; Becker and Grasso , 1985 ; Kontos et al. , 1985 ; Williams and Higgs , 1988 -RRB-	40168
phospholipase A2 activity -LRB- Hirata et al. , 1980 -RRB-	40168
phospholipase A2 activity	40168
Hirata	40195
et al. , 1980	40202
et al.	40202
1980	40210
the production of metabolites of the arachidonic acid cascade -LRB- Becker and Grasso , 1985 -RRB- thereby reducing the formation of free radicals -LRB- Hirata et al. , 1980 ; Becker and Grasso , 1985 ; Kontos et al. , 1985 ; Williams and Higgs , 1988 -RRB-	40231
the production of metabolites of the arachidonic acid cascade -LRB- Becker and Grasso , 1985 -RRB-	40231
the production	40231
metabolites of the arachidonic acid cascade	40249
metabolites	40249
the arachidonic acid cascade	40264
Becker and Grasso	40294
1985	40313
the formation of free radicals	40336
the formation	40336
free radicals	40353
Hirata et al. , 1980 ; Becker and Grasso , 1985 ; Kontos et al. , 1985 ; Williams and Higgs , 1988	40368
Hirata	40368
et al. , 1980 ; Becker and Grasso , 1985 ; Kontos et al. , 1985 ; Williams and Higgs , 1988	40375
et al. , 1980	40375
et al.	40375
1980	40383
Becker and Grasso , 1985	40389
Becker and Grasso	40389
1985	40408
Kontos et al. , 1985	40414
Kontos	40414
et al. , 1985	40421
et al.	40421
1985	40429
Williams and Higgs , 1988	40435
Williams and Higgs	40435
1988	40455
MP	40462
expression of tumor necrosis factor aplha	40478
expression	40478
tumor necrosis factor aplha	40492
the activation of nuclear factor-kappaB -LRB- Xu et al. , 1998 -RRB-	40532
the activation	40532
nuclear factor-kappaB -LRB- Xu et al. , 1998 -RRB-	40550
nuclear factor-kappaB	40550
Xu	40573
et al. , 1998	40576
et al.	40576
1998	40584
the intensity and duration of the inflammatory response -LRB- Xu et al. , 1998 -RRB-	40611
the intensity and duration	40611
the inflammatory response -LRB- Xu et al. , 1998 -RRB-	40641
the inflammatory response	40641
Xu	40668
et al. , 1998	40671
et al.	40671
1998	40679
these effects	40694
administration of MP	40726
administration	40726
MP	40744
a dose of 0.03 mg/kg -LRB- Young et al. , 1988 -RRB-	40750
a dose	40750
0.03 mg/kg -LRB- Young et al. , 1988 -RRB-	40760
0.03 mg/kg	40760
Young	40772
et al. , 1988	40778
et al.	40778
1988	40786
SCI	40826
MP	40831
the large dose of 30 mg/kg -LRB- Hall et al. , 1984 -RRB-	40858
the large dose	40858
30 mg/kg -LRB- Hall et al. , 1984 -RRB-	40876
30 mg/kg	40876
Hall	40886
et al. , 1984	40891
et al.	40891
1984	40899
this dose	40909
MP	40920
antioxidant effects , which allows it to scavenge free radicals , thus decreasing the oxygen radical-induced lipid peroxidation of cell membranes -LRB- Demopoulos et al. , 1980 -RRB-	40932
antioxidant effects	40932
it	40966
free radicals	40981
the oxygen radical-induced lipid peroxidation of cell membranes -LRB- Demopoulos et al. , 1980 -RRB-	41012
the oxygen radical-induced lipid peroxidation	41012
cell membranes -LRB- Demopoulos et al. , 1980 -RRB-	41061
cell membranes	41061
Demopoulos	41077
et al. , 1980	41088
et al.	41088
1980	41096
This mechanism	41103
independent of the glucocorticoid receptor-mediated actions of MP	41136
independent of the glucocorticoid receptor-mediated actions	41136
the glucocorticoid	41151
MP	41199
the large dose required to achieve these effects -LRB- Hall et al. , 1984 -RRB-	41219
the large dose	41219
these effects -LRB- Hall et al. , 1984 -RRB-	41254
these effects	41254
Hall	41269
et al. , 1984	41274
et al.	41274
1984	41282
this theory	41305
data demonstrating that synthetic steroids created to have greater antioxidant effects than MP	41321
data	41321
synthetic steroids	41345
greater antioxidant effects	41380
MP	41413
any glucocorticoid activity	41429
MP	41478
SCI -LRB- Hall , 1993 -RRB-	41500
SCI	41500
Hall	41505
1993	41511
The mechanism of action of ECs	41518
The mechanism	41518
action of ECs	41535
action	41535
ECs	41545
clues about the mechanism of action	41571
clues	41571
the mechanism of action	41583
the mechanism	41583
action	41600
ECs	41632
the growth of retinal ganglion neurites	41658
the growth	41658
retinal ganglion neurites	41672
coculture -LRB- Sonigra et al. , 1999 -RRB-	41701
coculture	41701
Sonigra	41712
et al. , 1999	41720
et al.	41720
1999	41728
that calciummediated signal transduction	41747
the growthpromoting properties of ECs , the calcium channel	41807
the growthpromoting properties	41807
ECs , the calcium channel	41841
ECs	41841
the calcium channel	41846
inhibitors verapamil and omega-conotoxin , as well as BAPTA-AM , a calcium chelator ,	41866
inhibitors verapamil and omega-conotoxin	41866
BAPTA-AM	41919
a calcium chelator	41929
the cocultures	41965
Application of these inhibitors	41981
Application	41981
these inhibitors	41996
the increase	42021
axonal growth	42037
the cocultures	42054
the conclusion	42081
ECs	42101
regeneration	42117
calcium-signaling pathways -LRB- Sonigra et al. , 1999 -RRB-	42138
calcium-signaling pathways	42138
Sonigra	42166
et al. , 1999	42174
et al.	42174
1999	42182
A subsequent study -LRB- Kafitz and Greer , 1999 -RRB-	42189
A subsequent study	42189
Kafitz and Greer , 1999	42209
Kafitz	42209
Greer , 1999	42220
Greer	42220
1999	42227
olfactory receptor cell extension in culture	42251
olfactory receptor cell extension	42251
culture	42288
exposure	42315
media conditioned by ECs	42327
media	42327
ECs	42348
the neurite growthpromoting properties of ECs	42369
the neurite growthpromoting properties	42369
ECs	42411
part	42433
diffusible factors	42451
Data supporting this idea	42471
Data	42471
this idea	42487
earlier this year	42510
ECs	42543
nerve growth factor , brain-derived neurotrophic factor , and glial cell linederived neurotrophic factor -LRB- Woodhall et al. , 2001 -RRB-	42569
nerve growth factor	42569
brain-derived neurotrophic factor	42590
glial cell linederived neurotrophic factor -LRB- Woodhall et al. , 2001 -RRB-	42629
glial cell	42629
neurotrophic factor -LRB- Woodhall et al. , 2001 -RRB-	42652
neurotrophic factor	42652
Woodhall	42673
et al. , 2001	42682
et al.	42682
2001	42690
these data	42705
two mechanisms of action forMP and insights	42725
two mechanisms	42725
action forMP and insights	42743
possible mechanisms for ECs , what they did not provide	42774
possible mechanisms	42774
ECs , what they did not provide	42798
ECs	42798
they	42808
any insight into the effects of using MP and ECs in combination	42832
any insight	42832
the effects of using MP and ECs in combination	42849
the effects	42849
MP and ECs	42870
combination	42884
the study described in this paper	42906
the study	42906
this paper	42929
These experiments	42946
ECs , not only alone but also in combination with MP ,	42982
ECs	42982
combination with MP	43014
combination	43014
MP	43031
regrowth and extension of CST axons	43055
regrowth and extension	43055
CST axons	43081
trauma	43097
the adult rat spinal cord	43107
fact	43137
no statistical difference	43152
the EC and MP/EC groups	43196
a significant increase in axon numbers	43234
a significant increase	43234
axon numbers	43260
13 mm caudal to the lesion	43279
13 mm caudal	43279
the lesion	43295
MP	43320
the regenerative properties of ECs	43335
the regenerative properties	43335
ECs	43366
Results using ECs to repair damaged spinal cord axons in animal studies	43371
Results	43371
ECs	43385
damaged spinal cord axons	43399
animal studies	43428
researchers	43472
the feasibility of transplanting ECs into human beings	43517
the feasibility	43517
ECs	43550
human beings	43559
Pig ECs	43573
a human complement inhibitory protein , which is intended to decrease rejection of the tissue	43624
a human complement inhibitory protein	43624
rejection of the tissue	43693
rejection	43693
the tissue	43706
human beings -LRB- Imaizumi et al. , 2000 -RRB-	43738
human beings	43738
Imaizumi	43752
et al. , 2000	43761
et al.	43761
2000	43769
transplantation into adult rats after dorsal column transection	43782
transplantation	43782
adult rats after dorsal column transection	43803
adult rats	43803
dorsal column transection	43820
pig EC transplants	43847
axonal regeneration , elongation , and remyelination	43875
axonal regeneration	43875
elongation	43896
remyelination	43912
impulse conduction	43939
the lesion site -LRB- Imaizumi et al. , 2000 -RRB-	43965
the lesion site	43965
Imaizumi	43982
et al. , 2000	43991
et al.	43991
2000	43999
rodent and porcine ECs	44015
repair	44046
SCI	44059
little	44064
human ECs	44097
ECs , obtained from adult human olfactory nerves removed from patients undergoing olfactory nerve resection ,	44118
ECs	44118
adult human olfactory nerves removed from patients undergoing olfactory nerve resection	44137
adult human olfactory nerves	44137
patients undergoing olfactory nerve resection	44179
patients	44179
olfactory nerve resection	44199
the demyelinated spinal cords of adult rats -LRB- Kato et al. , 2000 -RRB-	44249
the	44249
spinal cords of adult rats -LRB- Kato et al. , 2000 -RRB-	44266
spinal cords	44266
adult rats -LRB- Kato et al. , 2000 -RRB-	44282
adult rats	44282
Kato	44294
et al. , 2000	44299
et al.	44299
2000	44307
Extensive remyelination , characteristic of ECs ,	44314
Extensive remyelination	44314
characteristic of ECs	44339
characteristic	44339
ECs	44357
the lesion site	44386
human ECs	44422
remyelination -LRB- Kato et al. , 2000 -RRB-	44452
remyelination	44452
Kato	44467
et al. , 2000	44472
et al.	44472
2000	44480
These results	44487
ECs	44526
good potential for treating spinal cord injuries in human beings	44535
good potential	44535
spinal cord injuries	44563
human beings	44587
The experiments described herein	44601
The experiments	44601
ECs	44647
axonal regeneration and elongation	44659
recovery of DFR behavior	44708
recovery	44708
DFR behavior	44720
SCI in adult rats	44739
SCI	44739
adult rats	44746
The morphological and functional regenerative properties of ECs	44758
The morphological and functional regenerative properties	44758
ECs	44818
combination	44853
MP	44870
the ability of ECs to promote axonal regeneration	44883
the ability	44883
ECs to promote axonal regeneration	44898
axonal regeneration	44913
13 mm caudal to the lesion	44956
13 mm caudal	44956
the lesion	44972
that ECs	44998
their regenerative properties	45019
combination	45062
MP	45079
another clinically relevant step	45091
the spinal cord injury problem	45139
